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Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with a very 
poor patient prognosis (5-year survival of ≤ 7%). While transcriptional profiling has aided 
in the classification of this disease into at least two broader subtypes, this alone has so 
far been insufficient to inform on more nuanced patterns of oncogenic dependency. We 
hypothesized that a more comprehensive and granular characterization of PDAC disease 
diversity is required to establish relevant context for targeted therapy. To this end, we 
sought to establish an integrated platform to: i) more comprehensively characterize 
differential oncogenic signaling across our tumor models, and ii) establish a disease-
specific co-expression network to delineate transcriptional signatures underlying PDAC 
diversity. Utilizing an in vivo functional genomics platform, we developed custom libraries 
to first characterize and then expand on PDAC surface protein dependencies in PDX cell 
lines. In parallel, leveraging our internally established set of over 50 PDX models, we 
generated a PDAC co-expression network (PCEN) of dynamically expressed genes to 
inform on transcriptional signatures underlying disease diversity. Upon integration, we 
identified CRISPR-defined dependencies anchored within prominent anti-correlating 
gene-cluster signatures, including one differential signature that perfectly recapitulated 
the characteristics of classical and basal-like PDAC molecular subtypes on a continuous 
 
 vi 
scale. Additionally, through scRNAseq, this continuous scale was also observed 
intratumorally across PDX lines. Applying sgRNA direct-capture for targeted gene 
perturbation and sample multiplexing in scRNAseq, we validated PCEN-informed 
dependences (SMAD4, ZEB1, ILK) associated to the basal-like subtype intratumorally. 
Silencing these targets resulted in a significant and direction shift in the differential 
signature spectrum towards a more classical profile, coinciding with phenotypic response. 
These findings highlight this integrative network-anchored approach as a novel 
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Chapter 1: Introduction 
 
Pancreatic Ductal Adenocarcinoma (PDAC), the most common form of pancreatic cancer 
(85%), is a highly aggressive malignancy that frequently presents at an advanced stage, 
resulting in a very poor patient prognosis (5-year survival of 7%) and a limited timeframe 
for clinical intervention (1-year survival rate of 20%)1,2. Moreover, patients that present 
with metastases (>80%) have an average survival rate of less than one-year3. A limited 
range in early detection strategies, therapeutic options, and patient stratification 
opportunities contribute to PDAC presenting with one of the poorest survival rates 
amongst common cancers4. As a result, PDAC is projected to be the second most 
common form of cancer-associated death in the United States by 20305. A disease 
characterized by a high frequency of activating mutations in KRAS (90%), and additional 
recurring losses of the epithelial-associated tumor suppressors TP53 (66%), SMAD4 
(23%), and CDKN2A (19%), the relatively flat mutational landscape of this disease has 
so far not provided much opportunity for drug positioning or subtyping in the majority of 
tumors4. As a result, curative resection followed by adjuvant chemotherapy with the 
standard-of-care nucleoside analog, gemcitabine provides the greatest survival benefit to 
patients diagnoses with PDAC. In addition to gemcitabine alone, gemcitabine in 
combination with nab-paclitaxel, along with the FOLFIRINOX regimen, have shown to 
improve patient survival in late-stage metastatic tumors where surgical resection is not 
an option6. However, the PDAC tumor microenvironment has been shown to play a role 
in limiting the effectiveness of these chemotherapeutic strategies over time, driven by a 
combination of an overproduction of extracellular matrix components, pancreatic stellate 
cell stimulation, cancer associated fibroblast induction and other components derived 
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from tumor intrinsic and extrinsic factors7. Thus, while advancements in surgery and 
chemotherapy-based approaches have expanded on the limited therapeutic options 
available to PDAC patients, more advanced treatment strategies are required in order to 
make substantial improvements in patient survival. Further translationally-focused 
endeavors, rooted in the basic science efforts that continue to inform on the 
complexities of PDAC biology, are required to mirror the success that targeted 
therapy or checkpoint blockade strategies have had in other common tumor types.  
Recent advancements have started shine a light on opportunities for targeted 
therapy and patient stratification in PDAC by i) expanding the scope of what was 
previously considered “druggable”, ii) stratifying approved therapies, informed by success 
in other tumor settings, and iii) incorporating integrated transcriptomic information to aid 
in molecular subtyping. More specifically, novel opportunities in targeted therapeutics 
have been recently highlighted by the introduction of a novel KRASG12C inhibitor, AMG 
510. This small molecule represents the first successful direct inhibitor of mutant KRAS, 
made possible by a novel approach in fragment-based drug discovery known as 
Tethering8. In addition to development of novel inhibitors, the PDAC field has also recently 
expanded into successful strategies for targeted therapy stratification observed in other 
tumors. Recent success of the ongoing randomized POLO trial has showed that patients 
with germline BRCA mutations exhibit significantly increased survival following PARP 
inhibitor maintenance therapy in first-line treatment responders9. Significant 
advancements have also been made in defining PDAC molecular subtypes using 
transcriptomic signatures, with a consensus around two clinically associated cohorts 
termed “classical” and “basal-like”10,11. Additionally, recent efforts focusing on these 
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PDAC subtypes have sought to understand the underlying drivers of these transcriptomic 
signatures, implicating potential roles epigenetic regulation and copy-number 
amplifications in KRAS12,13.  
In this introductory chapter, I will expand on the clinical and biological 
complexities underlying PDAC lethality, and provide the necessary background to 
inform on the underlying logic of our context-forward functional genomics 
platform. More specifically, I will provide a brief introduction to i) the current clinical 
challenges in PDAC, ii) the influential components of PDAC diversity, and iii) 
leveraging molecular subtyping to annotate the PDAC disease spectrum beyond 
mutation profiles.  
1.1: Evolution and Current Challenges in PDAC Clinical Management  
1.1.1: PDAC Standard of Care  
In 1858, Jacob Mendez Da Costa’s microscopic diagnosis of PDAC was the first 
to formally categorize this highly lethal disease as a ductal adenocarcinoma, expanding 
on the early work of Giovanni Battista Morgagni and formally defining one of the most 
medically challenging cancers to date14. Over the course of the 20th century, several major 
treatment opportunities were made available for PDAC patients. One of the first major 
contributions to PDAC standard-of-care being the Whipple procedure, a two-stage 
pancreaticoduodenectomy popularized by Allen Whipple at the American Surgical 
Association in 1935, which would later evolve into a one-stage technique14. This 
procedure was originally employed to remove ampullary carcinomas, and would go on to 
be utilized as a major tool for early-stage PDAC resection14. Surgical resection currently 
provides the greatest survival benefit for PDAC patients15. Unfortunately, only 20% of 
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patients diagnosed with PDAC present with localized and resectable disease, extending 
5-year survival between 14% and 40%15-18.  
In addition to tumor resection, chemotherapy and radiotherapy are regularly 
employed in PDAC treatment. Chemotherapeutic strategies have continually made 
nuanced advancements in extending patient survival, starting with FDA approval of 
gemcitabine (2’,2’ - diflourodeoxycytidine) in 1996. Since approval of gemcitabine, this 
nucleoside analog has served as a major component in the standard of care for locally 
advanced and metastatic PDAC, replacing 5-flourouracil (5-FU), another antimetabolite 
that served as a thymidylate synthase inhibitor19. In addition to advancements in 
chemotherapeutic agents, avenues for leveraging chemotherapy in an adjuvant setting 
were also explored, with the hope of reducing tumor recurrence following surgical 
resection. In 2004, the European Study Group for Pancreatic Cancer (ESPAC) identified 
that adjuvant chemotherapy, specifically 5-FU treatment following surgical resection, 
significantly increased the median lifespan of patients20.  In 2007, adjuvant chemotherapy 
using gemcitabine was further annotated as a strategy to delay recurrent tumor formation 
following resection21. Along with adjuvant treatment for surgically resected tumors, more 
recent efforts have also focused on improving chemotherapeutic regimes to help improve 
the lifespan of patients diagnosed with advanced metastatic pancreatic cancer. 
Expanding on gemcitabine, the FOLFIRINOX chemotherapy regimen, a combination of 
folinic acid, 5-FU, irinotecan and oxaliplatin, was identified as a more effective treatment 
for advanced pancreatic cancer, compared to gemcitabine alone in 200822. Treatment 
options for late-stage tumors were further expanded upon in 2013, when the FDA 
approved gemcitabine and nab-paclitaxel combination to be a slightly less toxic 
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alternative to FOLFIRINOX for treating advanced pancreatic cancer23. Most recently, in 
2019, the American Society of Clinical Oncology has updated their treatment 
recommendation guidelines to incorporate FOLFIRINOX as an adjuvant treatment in 
patients who did not receive preoperative therapy. This was based on the success of 
adjuvant FOLFIRINOX, compared to adjuvant gemcitabine alone, in the phase III 
PRODIGE 24/CCTG PA.6 randomized clinical trial24. Finally, while adjuvant therapy has 
shown survival benefit, neoadjuvant chemotherapy is still currently considered 
experimental due to potential effects on perioperative morbidity and patient mortality25. 
These surgical, radiological and chemotherapeutic strategies remain in use as the 
standard of care for PDAC treatment today, with current general strategies outlined by 
the American Society of Clinical Oncology (ASCO).  
ASCO has published guidelines for the clinical management of PDAC based on 
three relevant disease states: potentially curable, locally advanced unresectable, and 
metastatic pancreatic cancer. Potentially curable pancreatic cancer (PCPC) is diagnosed 
as having no clinical evidence of metastatic disease, whereby primary surgical resection 
is approved for the primary tumor and regional lymph nodes, and is followed by 6 months 
of adjuvant chemotherapy24,26. In addition, preoperative therapy is recommended for 
patients presenting suggestive, although non-diagnostic evidence of tumor 
dissemination, and chemoradiation is provided to patients who did not receive 
preoperative therapy and present microscopically positive margins following systemic 
adjuvant chemotherapy26. Preoperative therapy may be applied in conditions where 
tumors have minor local infiltration, in order to shrink the tumor enough for resection26. 
Locally advanced, unresectable pancreatic cancer (LAPC) is present in more than half of 
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PDAC-diagnosed patients. This “locally advanced” distinction is largely undefined, and 
based on the observed extent of invasion into local vasculature24. Currently, the main 
clinical focus of LAPC is management of disease progression and symptoms with 
systemic chemotherapy or stereotactic body radiation therapy, as curative resection is 
normally not an option and rarely performed24. However, along with the challenge of 
tumor-burden induced symptom management, metastatic disease is exhibited in 30% - 
50% of patients with LAPC within only 3 months24. Patients presenting with metastatic 
pancreatic cancer (MPC) typically present with metastases in the liver and lung, and 
exhibit a 5-year survival of < 3%27. First line therapy for MPC is systemic chemotherapy, 
ranging from FOLFIRINOX (leucovorin, fluorouracil, irinotecan and oxaliplatin), to 
gemcitabine plus abraxane, to gemcitabine alone, in order of regimen aggressiveness27. 
The distinction of PDAC into these three categories: potentially curable, locally advanced 
unresectable, and metastatic pancreatic cancer, highlight a spectrum of disease with 
clear phenotypic implications. While these chemotherapy-based treatment strategies 
serve to extend patient survival, a better understanding of the genetic 
underpinnings that drive these ASCO-defined disease categories is needed in 
order to advance PDAC treatment strategies. This is especially prominent in the 
ongoing work seeking to incorporate targeted therapeutic strategies into PDAC 
standard of care.  
1.1.2: Targeted Therapeutic Strategies in PDAC  
While chemotherapy serves as the current foundation in PDAC standard of care, 
this strategy only serves to extend patient survival. In order to continue to advance PDAC 
treatment strategies beyond this current scope, targeted therapeutic strategies built on 
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the genetically validated context-specific dependencies are needed. In 2005, following a 
randomized phase III clinical trial, the FDA approved the tyrosine kinase inhibitor (TKI) 
erlotinib, in combination with gemcitabine, as a combination therapy for first line treatment 
for advanced pancreatic cancer28. At this time, erlotinib had already been approved for 
non-small cell lung cancer (NSCLC) in 2004, specifically to prolong survival following first-
line or second-line chemotherapy29. This small molecule targets the epidermal growth 
factor receptor (EGFR), a transmembrane glycoprotein and mitogenic driver 
overexpressed in 40% to 70% of patients30. Leveraging erlotinib to improve gemcitabine 
response as a first-line therapy was the first successful attempt at incorporating an 
established targeted therapeutic for PDAC treatment, resulting in a significant increase in 
patient survival of 2 weeks28. However, while technically significant, these findings 
highlighted the challenge in incorporating targeted therapy approaches without patient 
stratification. Thus, underscoring an inherent genetic inter- and intra-tumoral 
heterogeneity within the PDAC disease spectrum that poses a major challenge when 
attempting to use targeted therapeutic approaches in the clinic. More recently, the PDAC 
field has taken advantage of the established synthetic lethality between BRCA loss-of-
function mutations and poly ADP ribose polymerase (PARP) inhibition that was identified, 
and later FDA approved, for stratified breast cancer treatment31. The POLO trial, a phase 
III randomized clinical trial, which leveraged BRCA mutations to inform on the PARP 
context-specific application inhibitors as maintenance therapy, saw the first successful 
utilization of patient genomic data to aid in stratifying PDAC patients for context-specific 
treatment9. This culminated into the FDA approval of olaparib for PDAC in December, 
2019. One major limitation to this strategy, however, is that only a minority of PDAC 
 
 8 
patients present with mutations in BRCA1 (1.3%) or BRCA2 (2.1%)4. Nevertheless, 
leveraging BRCA mutations to aid in patient stratification for olaparib maintenance 
therapy represents a big step in the field towards personalized targeted therapy. The early 
non-stratified utilization of erlotinib and gemcitabine as a first-line therapy in non-
resectable tumors, and the later BRCA-informed stratification of olaparib as a 
maintenance therapy, represent success stories in adopting targeted therapeutics to 
improve PDAC patient survival. However, while leveraging targeted therapeutics 
originally designed around NSCLC and breast cancer aided in expanding on PDAC 
treatment options, the field has yet to develop a successful targeted therapy based solely 
on disease spectrum of pancreatic cancer30.  
1.1.3: KRAS (Kirsten rat sarcoma viral oncogene homolog) 
The RAS (rat sarcoma) gene superfamily includes five conserved gene families: 
Ras, Rho, Ran, Rab and Arf. Even within the Ras family itself, gene members can further 
be divided into six subfamilies: Ras, Ral, Rap, Rheb, Rad and Rit. Much like the other 
gene families and subfamilies, the Ras subfamily is comprised of 35 related proteins that 
serve as centralized switches for cell-signaling cascades through guanine triphosphate 
(GTP) binding and hydrolysis32. These GTPases, in combination with additional effectors 
and regulator proteins, modulate a vast array of signaling pathways ranging from mitosis 
to macropinocytosis33-35. Since their discovery, this RAS subfamily has been synonymous 
with cancer, and is currently one of the most well-studied oncogenic pathways36. In 1964, 
KRAS and HRAS were originally identified as viral genes contributing to the oncogenic 
characteristics of two strains of acute transforming retroviruses, specifically the Kirsten 
and Harvey strains33,34. Derived from the rat genome, these viral genes encoded 21 kDa 
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proteins (p21) provided the first evidence of the underlying mitogenic properties of these 
oncogenic proteins33,34,36. The human counterparts of these viral oncogenes would not 
be fully explored until the advent of DNA transfection into NIH/3T3 mouse fibroblasts, 
providing the first assay for oncogene detection using DNA derived from human tumor 
cells36,37. In 1982, these DNA transfection assays would famously be utilized to identify 
the human homologues of the viral ras genes previously identified in the Kirsten and 
Harvey retroviral strains38-40. Soon after this discovery, the genetic event driving HRAS 
and KRAS oncogenic potential was identified to be a single missense mutation in codon 
1238,41-43. This missense mutation was also identified in the ras genes of the Kirsten and 
Harvey retroviral strains. A transforming potential for NRAS would also later be identified 
in human neuroblastoma cell lines in 1983, cementing HRAS, KRAS, and NRAS as the 
feature oncogenic drivers in this RAS subfamily44. In addition to activating mutations in 
codon 12, additional activating missense mutation hotspots in these three RAS isoforms 
were later identified in codon 13 and codon 6145. Overall, the culmination of these early 
scientific efforts was essential in the discovery and molecular characterization of these 
RAS isoforms, providing insight into how specific missense mutations can convert these 
small 21 kDa GTPases into core oncogenic drivers critical to tumorigenesis.  
Among these isoforms, KRAS alone is the most frequently mutated oncogene 
across human cancers and also the predominant oncogenic driver in PDAC, with a 
prominent gain-of-function mutation frequency ≥ 90%4,32. KRAS serves a regulatory 
function for downstream signaling by cycling between GDP-bound inactive and GTP-
bound active states. These inactive GDP-bound and active GTP-bound states are 
subsequently controlled through the aid of guanine nucleotide exchange factors (GEFs) 
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and GTPase activating proteins (GAPs), with GEFs aiding in releasing bound GDP and 
GAPs serving aid in the hydrolysis of GTP in order to keep the RAS protein in a 
predominantly inactive state in normal quiescent cells32. Somatic missense mutations at 
the previously described codons 12, 13 and 61 all result in decreased GTPase activity by 
inhibiting GAP binding or the hydrolysis reaction itself46. As a result, the higher 
concentration of GTP vs. GDP in the cell, and the fact that KRAS has a higher affinity for 
GTP than GDP, results in a more persistently activated KRAS protein and persistent 
downstream signaling46.  
Up until recently, directly targeting KRAS has been a challenge due to the 
extremely high GTP affinity and amount of accessible GTP in the cell cytoplasm46. 
Previous efforts have sought block KRAS induced proliferative signaling by blocking 
downstream effectors, largely through the canonical MAPK and PI3K/AKT pathways46. A 
major challenge in treating these downstream pathways is the crosstalk that occurs 
between the PI3K and RAF pathways. Inhibition of ERK signaling results in an activation 
of PI3K/AKT signaling47, and perturbation of PI3K results in an increase in ERK activity48. 
Unfortunately, pharmacological inhibition of both pathways have been met with toxicity49. 
Upstream targeting of KRAS localization to the inner plasma membrane has also been 
explored, through specific targeting of the post-translational modifications required for 
KRAS-binding to the cytosolic face of the plasma membrane. However, development and 
implementation of farnesyltransferase inhibitors to block the post-translational 
mechanism of negating negative-charge induced plasma membrane repulsion have yet 
to show promise in vivo46. Finally, recent developments have led to the first phase 1 
clinical trial of AMG 510, a KRASG12C-specific inhibitor. AMG 510 works through 
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covalently binding to the P2 pocket present in inactive GDP-bound KRAS50. As a result 
of the phase 1 trial, only 11% of patients exhibited Grade 3 and 4 toxic effects as a result 
of treatment50. Currently, AMG 510 is on track to being the first FDA approved mutant 
KRAS inhibitor. With these recent developments, understanding compensatory avenues 
of resistance following ablation of mutant KRAS, and determining whether these avenues 
are inherent to the tumor population or adaptive mechanisms, is likely going to become 
even more critical in the coming years. For example, recent efforts have highlighted how 
Yap1/Tead2 complex can serve to activate the cell cycle following Kras ablation in Kras-
driven mouse models51. Additional work has also highlighted the potential to target the 
mitochondria using oxidative phosphorylation inhibitors in selected PDAC cancer stem 
cells that survive mutant Kras ablation52. Thus, even in the context of a direct KRAS 
inhibitor, a more comprehensive understanding of potential compensatory 
mechanisms are needed in order to clinically address this treatment resistant 
tumor.  
1.1.4: Addressing the Tumor Microenvironment  
In addition to compensatory mechanisms and limited avenues for targeting KRAS-
driven oncogenic signaling, multiple features of the PDAC microenvironment have been 
shown to play a role in blocking therapeutic delivery or contributing to chemoresistant 
signaling. One of the most prominent features of PDAC tumors is the desmoplastic 
stromal component, a mixture of fibroblasts, extracellular matrix (ECM) and immune cells 
that encompasses the tumor. This stromal component raises the interstitial pressure 
around blood vessels, ultimately restricting the tumor of oxygen, nutrients and delivery of 
chemotherapeutic compounds53,54. Additionally, activated pancreatic stellate cells (PSCs) 
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serve to confer chemo-resistance through paracrine signaling. Such mechanisms include 
the SDF1/CXCR4 axis resulting in activation of IL-6 autocrine loop55. Finally, the induction 
of hypoxia has been show to contribute to chemoresistance, alter tumor metabolism, and 
promote EMT and tumor invasion by increasing Twist expression53,56.  
1.1.5: Summary  
Since its initial characterization, Pancreatic Ductal Adenocarincoma has presented 
as a highly complex and lethal disease. Plagued by late-stage diagnosis and 
chemoresistance, treatment for PDAC has largely straddled complete tumor resection 
and quality of life management. While major advances have been made in understanding 
the nature of gain-of-function mutations in KRAS and the compensatory nature of KRAS 
downstream signaling, clinical options largely remain limited to chemotherapy. However, 
recent advancements in targeted therapeutic approaches are finally starting to put a dent 
in the armor of this highly lethal disease, highlighted by the recent success of the phase 
1 clinical trial for AMG 510, a KRASG12C inhibitor. Continuing a logical and step-wise 
understanding of the complex biological signatures that pancreatic tumors 
leverage for mitogenic signaling and survival will eventually contribute to 
increasing clinical opportunities for this disease.  
1.2: RNAi, CRISPR-Cas9 and Functional Genomics  
1.2.1: Genetic screening using RNA interference (RNAi)  
Genetic screens are a powerful tool that allows for the comprehensive phenotypic 
analysis of large gene sets, ranging from focused libraries to the entire genome. In terms 
of RNAi, screens fall into one of two categories: positive selection screens and negative 
selection screens. Positive selection refers to a positive selection advantage, or an 
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increase in fitness when presented to a specific selective pressure, while negative 
selection refers to a negative selection advantage, or decrease in fitness under selective 
pressure. Selective pressure can take many forms, ranging from mutation induction, gene 
expression, or introduction of a drug. Here, I will describe the discovery and implantation 
of RNAi as a high-throughput reverse genetics system for establishing selective pressure 
through target-specific inhibition.  
In 1998, the discovery of double-stranded RNAs (dsRNAs) in C. elegans with the 
capacity for post-transcriptional silencing of mRNAs led to the development of a unique 
tool that would allow for a rapid functional characterization of the genome57. While earlier 
implementations of loss-of-function screening was possible, it was normally limited to 
time-consuming, less precise or less stable technologies such as saturation mutagenesis, 
antisense RNAs, and homologous recombination. This dsRNA mechanism, termed RNA 
interference (RNAi), provided a novel means for rapid mRNA degradation utilizing ~21 
nucleotide double stranded RNAs, without inducing an interferon response in mammalian 
cells58-60. There are two types of small RNA molecules, small interfering RNAs, double 
stranded RNAs that exhibit perfect binding to mRNA targets and derived exogenously 
through viruses, and microRNAs, endogenously produced single stranded hairpin loops 
that fold back onto themselves with imperfect binding61.  As a result of imperfect mRNA 
binding, miRNAs have the potential to bind to multiple mRNAs, allowing them to serve as 
signaling regulators61. For both miRNAs and siRNAs, post-transcriptional silencing and 
mRNA degradation require a mature RNAi induced silencing complex (RISC). Both 
miRNAs and artificial short hairpin RNAs (shRNAs) form a stem loop to allow constitutive 
expression of siRNA in the cell, with initial RNA processing being through the class 2 
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ribonuclease III enzyme Drosha, a double stranded endoribonuclease (transfected 
siRNAs bypass the need for Drosha)61. These hairpin structures are then exported from 
the nucleus through Xpo5, and further processed by Dicer into shorter fragments61. These 
fragments are unwound by Ago2, and the passenger strand is degraded and the guide 
strand is incorporated into the RISC complex. Here, the siRNA serves to guide this 
silencing complex to the mRNA localized in processing bodies (P-bodies), where 
Argonaute proteins cleave the mRNA61. Cleavage requires a near perfect match between 
the guide siRNA strand and the mRNA61. As a result, miRNA regulation normally occurs 
through translational repression rather than mRNA degradation61.  
As a result, lentiviral delivery of shRNAs or lipid-based transfection of siRNAs, 
originally served as highly useful tool for rapid mRNA degradation, whereby the 
respective implantation of pooled lentiviral protocols or arrayed large-scale reverse 
transfection strategies allowed for rapid whole genome loss-of-function (LOF) screens. In 
addition, these techniques also allowed for targeted screening using defined Kinome, 
Epigenome, or Druggable libraries. However, while these siRNAs served to provide a 
means for rapid mRNA depletion, errors in off-target mRNA binding have been a 
prominent negative feature of this technology62. Off-target binding, resulting in false 
positive phenotypes, essentially required the need for phenotype rescue in order to 
validate any RNAi-defined target. Recent findings have pointed to the fact that a lack of 
siRNA rescue in the context of these off-target toxicities has resulted in the 
misidentification of cancer vulnerabilities63. Despite these challenges, the advent of RNAi 
functional genomics has paved the way for rapid genetic screening in tumor models.  
1.2.2: CRISPR-Cas9 based screening   
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Over the past 8 years, novel genetic engineering technologies have emerged that 
have provided refined ways to introduce pressure onto biological systems. Specifically, 
with the discovery and implementation of CRISPR-Cas9, genetic screening in cancer 
models has become more precise and sensitive, allowing for a more robust 
characterization of potential oncogenes in tumor model systems. This brief overview will 
introduce the work that contributed to the discovery and mechanistic annotation of 
CRISPR-Cas9, as well as its contribution to reverse genetic platforms.   
Clustered regularly interspaced short palindromic repeat (CRISPR) DNA 
sequences were originally identified in 1987 in E.coli64. Due to the prominence of these 
repeat elements in bacteria and archea, distinguished from typical tandem repeats by 
being separated by non-repeating sequences, researchers originally explored these 
sequences as potential viral sequences. In addition, nearby to these CRISPR sequences, 
conserved CRISPR-associated (Cas) genes were also notably observed65. Original 
evidence underlying the role of CRISPR in bacterial systems showed that, following 
bacteriophage exposure, Streptococcus thermophilus integrated viral sequences into its 
genome which served to direct Cas enzymes as a resistance mechanism66. It was this 
discovery that led to the additional characterization of the role sequence-derived CRISPR 
RNAs (crRNA) in directing Cas activity, and the requirement for proto-adjacent motifs 
(PAMs) CRISPR-based activity and resistance67,68.  
Following these initial findings, it was quickly becoming apparent that this system 
had the potential to be leveraged as a genetic tool. The transferable nature of this 
CRISPR system was observed across bacteria models69. In addition Cas protein 
identified in S.thermophilus, Cas9, was identified as having DNA catalytic activity through 
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concordant activity of two short RNAs and an NGG PAM sequence70. With these 
observations in place, it was the seminal work by Charpentier and Doudna, which was 
published in 2012 and awarded the Nobel Prize in 2020, that established CRISPR-Cas9 
as a novel tool for genomic editing64. Specifically, this work highlighted the ability to 
selectively target the genome using a single guide RNA (sgRNA), a chimeric RNA based 
on the merging of sequenced specific crRNAs and structural Cas9-recruiting trans-
activating crRNAs (tracrRNA) normally expressed in endogenous Cas9 settings64. 
Several prominent efforts then confirmed that sgRNA-directed CRISPR-Cas9 could be 
leveraged in eukaryotic settings71-73, allowing for site-directed recruitment of Cas9 and 
selective double strand breaking. As a result, site-directed Cas9 cutting opened up the 
opportunity for precise gene editing through homology-directed repair (HDR), or for the 
induction of frameshift mutations through non-homology end joining (NHEJ). Notably, the 
requirement of a PAM motif for Cas9 significantly reduces off-target effects in this system 
compared to RNAi. CRISPR based knockout also has the potential for increased 
sensitivity, as RNAi based knockdown becomes less effective at moderate-to-lower 
expression levels74. In addition, this PAM-driven precision has also allowed for a reduction 
of library complexity in CRISPR libraries, with only 4 - 6 sgRNAs required per gene. 
However, for the classical CRISPR-Cas9 system, two major challenges persist: i) 
addressing in-frame indel formation when preparing pooled knockouts, and ii) timing indel 
formation and protein knockout when studying highly essential genes. In both settings, 
positive selection of in-frame indels can influence the perceived signature and phenotype 
when studying highly essential targets. However, recent advancements in CRISPR 
platforms (such as CRISPRi) have helped to address these challenges. Overall, the 
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implementation of CRISPR-Cas9 towards genetic screening have provided a significant 
improvement in genetic screen data precision and quality compared to RNAi74.  
1.2.3: Network-based approaches for interpreting CRISPR screening data  
Based on the increased precision of Cas9 gene-editing compared to RNAi, as well 
as the continued refinement of dropout analysis through computations frameworks like 
BAGEL (Bayesian Analysis of Gene EssentiaLity), there is an opportunity to expand the 
application of dropout data beyond a single-target focus. In this way, high quality CRISPR 
screen data has the potential to be applied in a similar fashion to whole exome 
sequencing or RNA sequencing, providing an additional layer of characterization to tumor 
models and by validating dependencies rather assuming vulnerabilities associated to 
known mutation, epigenetic or transcriptomic profiles. As an example, CRISPR based co-
essentiality networks using human cancer cell lines have been shown to have the 
capacity to inform on novel targets, predict gene function, and aid in identifying protein 
complexes75,76.  
1.2.4: Summary 
Over the past 14 years, the capacity for reverse genetics has expanded 
dramatically. The initial discovery and implementation of high-throughput siRNA and 
lentiviral shRNA systems laid the groundwork for whole genome and custom genetic 
screening. Despite the early limitations in RNAi-based screening, the ability to rapidly 
degrade mRNA through selective recruitment of the RISC complex provided an 
indispensable tool for cancer research and drug discovery. In addition to RNAi, the recent 
and rapid advancement in CRISPR-Cas9 screening technology has provided new 
avenues for genetic perturbation and site-directed modification in eukaryotic genomes. 
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The increased precision and sensitivity of this technology, combined with improved 
computational platforms to aid in quantifying gene-level dropout, provides a much more 
refined look into the dependency spectrums underlying our tumor models. By leveraging 
these dependency spectrums to inform on biological patterns, rather than applying 
a single-target approach, CRISPR-Cas9 based screening has the potential to 
provide a more comprehensive form of tumor characterization.  
1.3: Oncogenic Diversity and Molecular Subtyping in PDAC 
1.3.1: Mutation-based Diversity 
Relative to other tumor types, PDAC exhibits a relatively flat mutation landscape, 
largely driven by gain-of-function mutations in KRAS (90%), which is followed-up at lower 
frequency with loss-of-function mutations in TP53 (64%), SMAD4 (23%) and CDKN2A 
(17%)4. As a result, therapeutic efforts have largely focused on addressing KRAS 
associated signaling, both indirectly and directly. However, whole exome sequencing of 
PDAC patient biopsies reveal less frequent mutations (<10%) that can serve to diversity 
the oncogenic signaling heterogeneity we observe across these tumors4. Specifically, 
mutations in proteins involved in SWI/SNF nucleosome remodeling (ARID1A (8%), 
ARID1B (0.5%), SMARCA1 (0.8%), SMARCB1 (0.5%)), DNA damage response (ATM 
(4%), BRCA1 (1.3%), BRCA2 (2.1%)), and histone methylation (MLL2 (0.8%), MLL3 
(0.5%), KDM6A (03%)), are all prevalent at low frequency in PDAC4. Even though 
truncating and missense mutations in these genes present at low level across patient 
cohorts, these rarer genomic events can have a large impact in presenting tumors. 
Specifically, ARID1A loss in mouse PDAC tumors results in poor differentiation and 
mesenchymal features, as well as increased clonogenic and migratory properties77. Along 
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with SWI/SNF proteins, RNA sequencing of tumors with mutations in histone 
methyltransferases MLL2 and MLL3 show an increase in genes involved in proliferation, 
and chromatin regulation78.  While the exact mechanism is unknown for many of these 
less frequent PDAC mutations, it is hypothesized that many of these genomic events 
result in changes in the transcriptome that provide a selective advantage to the tumor. 
Finally, although these mutations present at low frequency, identifying context-specific 
vulnerabilities associated to these mutations provides a personalized avenue for 
treatment in presenting PDAC patients. As previously discussed, this was prominently 
highlighted by the recent FDA approval of PARP inhibitors as maintenance therapy, which 
highlighted progression free survival in a randomized phase 3 clinical trial focusing on 
PDAC patients presenting germline BRCA1 and BRCA2 mutations9.  
1.3.2: Transcriptomic subtyping and Epithelial-to-Mesenchymal Transition 
Due to the relatively flat mutational landscape in PDAC, transcriptomic signatures 
have become the primary means of pancreatic tumor classification. These recent efforts 
in PDAC molecular subtyping sought to characterize disease heterogeneity by leveraging 
clinical features to refine associated transcriptomic signatures10-13. These efforts have 
largely coincided with the advancement of transcriptomic profiling, starting with array-
based hybridization techniques and expanding into next generation RNA sequencing, or 
RNAseq. Multiple groups have sought to leverage transcriptomic profiling in order to 
inform on PDAC heterogeneity beyond the mutational landscape. Early work by Collison 
et al. (2011) used hybridization-based RNA characterization on untreated primary 
microdissected PDAC tumor samples and defined three subtypes in PDAC: classical, 
quasi-mesenchymal and exocrine11. Interestingly, these quasi-mesenchymal tumors 
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correlatives to higher tumor grade and poorer patient prognosis, while classical tumors 
elicited an increased KRAS dependency and expressed endodermal markers11. A few 
years later, Moffitt et al. (2015) refined an orthogonal approach by applying a virtual 
microdissection on primary PDAC tumor resections that categorized PDAC into two 
prominent subtypes, classical and basal-like10,11. Here, Moffitt almost completely 
recapitulated Collison’s findings for the classical subtype (defining 20/22 of Collison’s 
classical subtype defining genes), while also highlighting a “basal-like” signature similar 
to basal-like breast cancer profiles11. In addition, this basal-like signature was found to be 
most similar to the Collison quasi-mesenchymal subtype. Following Moffitt, Bailey et al. 
(2016) sought to leverage unsupervised clustering following transcriptomic profiling of 
bulk tumors, and leveraged an in-house genomic metric to estimate tumor cellularity11.  
Using this approach, they expanded into four PDAC subtypes: squamous, pancreatic 
progenitor, immunogenic and aberrantly differentiated endocrine exocrine (ADEX)11. 
Upon further evaluation, it was determined that the Collison classical subtype, Moffitt 
classical subtype, and the Bailey progenitor subtype represented similar orthogonal 
signatures11. In addition, overlap in the Collisson quasi-mesenchymal subtype, Moffitt 
basal-like subtype, and Bailey squamous subtype were also observed across studies, 
although not with the same degree of overlap observed in the classical/progenitor 
subtypes10,11. This signature overlap points to difference in tumor sample collection, tumor 
signature isolation, and different approaches in transcriptomic analysis as contributors 
towards differences across these studies. This was further clarified after the Collison 
exocrine-like subtype and the Bailey ADEX subtype were found to be a result of normal-
epithelium contamination11. Furthermore, the Bailey immunogenic subtype was also 
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found to be due to stromal contamination11. As a result, molecular subtyping in PDAC is 
currently focused on two transcriptomic subtypes, and is currently centered on the Moffitt 
classical and basal-like classifications10. These classical and basal-like subtypes were 
refined largely based on clinical features, and serve to inform on patient prognosis. 
However, these subtypes do not yet inform on treatment strategies10,11. Recently, these 
molecular subtypes have also been further explored in order inform on the potential 
drivers underlying this molecular diversity, along with expanding on the granular, and 
intratumoral, scope of these Classical and Basal-like cohorts12,13. These findings 
implicated epigenetic mutations and copy-number events, along with amplifications in 
mutant KRAS, in driving these molecular subtypes12,13. However, due to the consensus 
clustering nature of this subtyping approach, tumors are forcefully assigned to one of two 
molecular profiles using a limited gene set. As a result, i) there is no capacity to observe 
these tumors on a spectrum, and ii) there is not an avenue for associating CRISPR-
defined dependencies within these refined gene sets. Moreover, although these subtypes 
likely represent only the most prominent transcriptional signature across tumors.  
1.3.4: Summary  
The limited mutation profile of PDAC, while contributing to tumor heterogeneity, 
does not aid in informing on context-specific vulnerability beyond leveraging germline 
BRCA mutations to stratify patients for PARP inhibitor maintenance therapy. The most 
established subtyping strategy for PDAC subtyping is the Moffitt signature, which uses 
consensus clustering to assign tumors into ”classical” and “basal-like” groups. While this 
gene signature provides prognostic value, it does not serve to comprehensibly capture 
PDAC diversity, nor does it inform on context-specific dependency.  
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Chapter 2: Methods 
 
This work is based on efforts outlined in our recent BioRxiv submission “Diversity Across 
the Pancreatic Ductal Adenocarcinoma Disease Spectrum Revealed by Network-
Anchored Functional Genomics” by Rose and Srinivasan, et al. (2020), DOI: 
https://doi.org/10.1101/2020.09.17.302034. As co-first author, Sanjana Srinivasan 
provided substantial computational support for this effort, enabling our findings. The 
manuscript is currently under review.  
PDX models  
A total of 49 models were obtained from the labs of Dr. Michael Kim (Department 
of Surgical Oncology, MD Anderson Cancer Center) and Dr. Scott Lowe (Memorial Sloan 
Kettering Cancer Center)79,80. PDXs were propagated and maintained in NOD scid 
gamma (NSG) mice carrying NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (Jackson Labs).   
Moffitt Classification 
Moffitt classification of Classical and Basal was assigned to the 49 PDX models 
using log normalized and scaled counts of 21 classical and 25 basal genes for PDX PDAC 
model classification described by consensus clustering into two groups using the R 
package ConsensusClusterPlus81. The clusters were manually assigned as classical and 
basal based on high expression of each group of genes. 
Cell Culture  
PDX cell lines were seeded in treated tissue-culture plates (Corning) in DMEM/F12 
medium (Gibco) supplemented with 10% Fetal Bovine Serum (Gibco), Penicillin (50 
units/mL) and Streptomycin (50 µg/mL) (ThermoFischer Scientific). Phosphate Buffered 
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Saline (PBS) was utilized prior to trypsinization and for general cell washing purposes 
(Thermo Fisher Scientific). Cells were regularly trypsonized (0.25%, Trypsin-EDTA, 
Gibco) prior to reaching 70% - 80% confluence, and maintained on 10 cm and 15 cm 
treated tissue-culture dishes (Corning). Viable cells were counted using a Cellometer mini 
and 0.2% Trypan Blue staining (Nexcelom).  
Lentiviral Transduction 
Second generation packaging plasmids (VSVG, pMD2.G) were leveraged for 
packing and lentiviral production in HEK293T. Briefly, media was replaced following 14 
hours of transfection into HEK293T cells, which were then cultured for an additional 48 
hours. Media was then run through a 0.45 µm syringe filter, and ultracentrifuged. Viral 
pellets were resuspended in PBS and stored at - 80 ºC until use.  
BrdU Straining and Cell Cycle Analysis  
A BD Pharmigen BrdU Flow Kit (Catalog No. 559619) was utilized for cell cycle 
analysis. Cells were collected 72 hours post puromycin selection, counted and seeded at 
1x106 cells per 10 cm tissue culture dish (Corning), and allowed to grow in culture for an 
additional 24 hours before the introduction of BrdU for 16 hours. After BrdU incorporation, 
cells were fixed and stained (anti-BrdU and 7AAD) for FACs analysis.  
Annexin-V Staining  
Annexin V and 7AAD staining was conducted 96 hours post puromycin selection 
using a BD FITC Annexin V Apoptosis Detection Kit (Catalog No. 556547).  
Design and Construction of Custom RNAi Library  
The original RNAi custom library, constituted by 2,653 shRNAs targeting PDAC-
prioritized proteins associated to the extracellular face of the plasma membrane, was 
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constructed using chip-based oligonucleotide synthesis and cloned into a pRSI17cb-U6-
sh-13kCB18-HTS6-UbiC-TagGFP2-2A-Puro lentiviral vector (Cellecta) as a pool. PDAC-
prioritized surface proteins (including proteins with evidence of mislocalization) were 
selected based on tumor-specific overexpression compared to matched-normal tissue, 
copy number vs. RNA expression correlation, and SILAC screening for KRAS 
dependency35. Significant tumor-specific overexpression and copy number vs RNA 
expression were determined for the full transcriptome, and subsequently refined using an 
internally curated list of select extracellular proteins containing transmembrane domains, 
GPI-anchored proteins and proteins with evidence of membrane mislocalization. Tumor-
specific overexpression vs. matched normal tissue was defined based on two matched-
normal bulk tumor microarray datasets (FC ≥ 1.5, q < 0.005, ArrayExpress: E-GEOD-
15471, EG-GEOD-28735), and further refined for tumor-specific expression (FC ≥ 1.5) by 
using a microarray dataset composed of micro-dissected samples (ArrayExpress: E-
MEXP-1121/950)82-86. Positive Spearman correlations (rho ≥ 0.35, q < 0.005) of copy 
number vs. RNA expression were calculated based on available TCGA level 3 data 
derived from the 07/15/2014 dataset87. False discovery rate for bulk tumor microarray 
datasets and for copy number vs. RNA expression correlations was calculated using the 
“qvalue” Bioconductor package88. Genes derived from published data characterizing 
KRAS dependent surface protein localization, conducted across three iKRAS p53L/+ 
mouse60 tumor-derived cell lines, were also incorporated into the library based on 
previous work35. The shRNAs targeted 241 genes, with 10 shRNAs/gene. Targeting 
sequences were designed using a proprietary algorithm (Cellecta). The oligo 
corresponding to each shRNA was synthesized with a unique molecular barcode (18 
 
 25 
nucleotides) for measuring representation by NGS. Negative controls consisted of 
shRNAs targeting Luciferase, and positive controls consisted of shRNAs targeting RPL30 
and PSMA1. In addition, we incorporated shRNAs targeting KRAS into the library to serve 
as additional controls for the PDAC PDX lines.  
RNAi Screening in vivo and in vitro 
Using the custom barcodes lentiviral shRNA library, PDX lines (PATC69, 
PATC124, PATC53 and PATC153) were transduced in vitro using 8 µg/mL Polybrene 
(Sigma-Aldrich). Libraries were transduced at 1000X coverage and multiplicity of infection 
(MOI) of 0.3.  Media was replaced after 14 hours, and at 48 hours, and MOI was 
confirmed by checking GFP percentage with flow-cytometry 48 hours post-transduction. 
Immediately following MOI confirmation with flow cytometry, 2 µg/mL Puromycin (Thermo 
Fisher) was added to each transduced cell population for 72 hours. Immediately following 
Puromycin selection, a Reference population was collected (1000X) and stored at -80 ºC. 
Remaining cells were split and moved into in vitro and in vivo settings. Three independent 
in vitro screens were seeded (1000X) into 15 cm treated plates (Corning). For in vivo 
implantation, cells were combined into 1:1 PBS/Growth-Factor Reduced Matrigel 
(Corning), and injected orthotopically at 1000X coverage per mouse. Immunodeficient 
NOD SCID mice were leveraged for in vivo screening. For in vitro screening populations, 
cell populations were collected at 10, 20 and 30 days post Reference collection. For in 
vivo screening, the entire pancreas and tumor of each mouse was collected at day 30. 
For each condition, cells were lysed using SDS and DNA was sheared using sterile 23 
gauge 1 inch needles (Becton Dickinson). Tumor DNA was isolated using 
Phenol:Chloroform extraction and Ethanol precipitation. A Nested PCR strategy was 
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utilized to amplify and prepare barcode populations for next-generation sequencing 
(Cellecta). Redundant siRNA activity (RSA) analysis was applied to rank targets for each 
PDX model and screen setting89.  
Design and construction of custom CRISPR Library 
The custom CRISPR-Cas9 sgRNA library was constituted by 3,367 sgRNAs and 
designed to both incorporate and expand upon the original RNAi-defined targets. The 
library was constructed using chip-based oligonucleotide synthesis and cloned into a 
pRSG16-U6-sg-HTS6C-UbiC-TagRFP-2A-Puro lentiviral vector (Cellecta) as a pool. 
RSA was used to rank essential genes from shRNA screens. Genes were curated based 
on RSA < 0.05 and FC < -2 in at least one model (N=100). Curated gene targets were 
further annotated by incorporating neighbors with a PPI score ≥ 0.80 (STRING, version 
10), and TPM (transcripts per million) > 2 in that model47. In addition, 50 non-essential 
genes and 50 essential genes were added to have a final set of 654 genes90. 
CRISPR Cas9 Screening in vivo and in vitro 
Using the custom barcodes lentiviral sgRNA library, PDX lines (PATC69, 
PATC124, PATC53 and PATC153) containing the lentiCas9-blast vector (addgene, 
plasmid #52962) were transduced in vitro using 8 µg/mL Polybrene (Sigma-Aldrich). PDX 
lines transduced with Cas9 were constantly kept at 10 µg/mL Blasticidin (Thermo Fischer 
Scientific). Libraries were transduced at 1000X coverage and a multiplicity of infection 
(MOI) of 0.3.  Media was replaced after 14 hours, and at 48 hours, and MOI was 
confirmed by checking RFP percentage with flow-cytometry 48 hours post-transduction. 
Immediately following flow cytometry, 2 ug/mL Puromycin (Thermo Fisher) was added to 
each transduced cell population for 72 hours. Immediately following Puromycin selection, 
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a Reference population was collected (1000X) and stored at -80 °C. Cells were allowed 
to culture for an additional 12 days in order to allow for some initial sgRNA-directed cutting 
prior to starting the in vivo screen, to reduce potential noise derived from disproportional 
cell doubling following orthotopic implantation. A secondary Reference (1000X), at the 
time of injection, was then collected. Remaining cells were split and moved into in vitro 
and in vivo settings. Three independent in vitro screens were seeded (1000X) into 15 cm 
treated plates (Corning). For in vivo implantation, cells were combined into 1:1 
PBS/Growth-Factor Reduced Matrigel (Corning), and injected orthotopically at 1000X 
coverage per mouse. Immunodeficient NSG mice were leveraged for in vivo screening. 
For in vitro screening populations, cell populations were collected at 10, 20 and 30 days 
post injection and secondary Reference collection. For in vivo screening, the entire 
pancreas and tumor of each mouse was collected at day 30 post injection. DNA extraction 
and barcode library preparation were conducted in similar fashion to the RNAi screens. 
For each condition, cells were lysed using SDS and DNA was sheared using sterile 23 
gauge 1 inch needles (Becton Dickinson). DNA was isolated using Phenol:Chloroform 
extraction and Ethanol precipitation. Nested PCR was utilized to amplify and prepare 
barcode populations for NGS (Cellecta). 
Single Cell Data Collection 
Samples for PATC69, PATC124 and PATC53  
Seurat version 3.191 was used to analyze all single cell analysis. Each of the lines, 
PATC124, PATC53 and PATC69 were analyzed separately. PATC53 contained two 
replicates, which were merged for analysis. For all PDX cell lines, single cells with a 
minimum of 350 expressed genes and less than 10% mitochondrial reads were retained. 
 
 28 
Genes expressed in less than 3 cells and mitochondrial genes were removed from further 
analysis. The data was log normalized, transformed using the “vst” function with top 2000 
variant genes. The total RNA count, cell cycle score and mitochondrial reads were 
regressed out. For PATC124, principal-component analysis and uniform manifold 
approximation and projection (UMAP) with the first 15 dimensions was performed, 
followed by identifying clusters using a resolution of 0.15. For PATC69, principal-
component analysis and uniform manifold approximation and projection (UMAP) with the 
first 15 dimensions was performed, followed by identifying clusters using a resolution of 
0.10. PATC53 contained two replicates, which were integrated as one dataset following 
normalization and variant stabilization. Total RNA count, cell cycle score and 
mitochondrial reads were regressed out of the integrated dataset, and PCA and UMAP 
on first 15 dimensions was performed, further identifying clusters using a resolution of 
0.10. 
Multiplex IHC-IF staining and data analysis 
Formalin fixed and paraffin embedded (FFPE) PATX samples were sectioned into 
3 µm thick sections and placed on positive charged slides. Sections were deparaffinised 
by baking at 60 ºC for 1 hour, then rehydrated by serial passage thorough xylene and 
graded alcohol. All sections were subjected to an initial heat-induced epitope retrieval 
(HIER) in 10 mM citrate buffer with 0.05% Tween20, pH 6.0, at 95 ºC for 15 minutes using 
a BioGenex EZ retrieval microwave. Subsequent HIER for Opal development was done 
using fresh citrate buffer at 95 ºC for 10 minutes. All sections were initially blocked for 
endogenous peroxidase using Bloxal (Vector Labs SP6000). After and before each 
primary incubation, sections were blocked using 2.5% serum (Vector Labs S1012). Opal, 
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indirect, and direct immunofluorescence methods were used. First node protein targets 
were developed using Opal methods, VSIG1 (Thermofisher MAB 4818, at 1/2000), and 
Vimentin (Cell Signaling Technologies 5741, at 1/1600). Ki67 (Cell Signaling 
Technologies 9129, at 1/400) was developed indirectly using anti-rabbit secondary, Alexa 
680 (Thermofisher A32802, 1/500). Lastly, HLA conjugated to Alexa 647 (Abcam 199837, 
at 1/1000) was used to aid in tissue segmentation. Sections were then counterstained 
with DAPI. 
Slides were imaged using Vectra 3.0 Automated Quantitative Pathology Imaging 
System (Akoya Biosciences). Image processing and analysis was performed using 
inForm Software v2.4 (Akoya Biosciences). For a subset of images from each PATX, the 
following was performed: Images were unmixed and autofluorescence was removed. 
Then, tissue was segmented as tumor, stroma or other based on training regions and 
pattern recognition of DAPI and HLA stain. This was followed by cell segmentation using 
DAPI and HLA to segment nuclei, cytosol, and membrane. Phenotyping was performed 
for each marker individually by selecting representative positives for algorithm training 
and allowing the software to select the rest. Batch analysis of all images was performed 
using the segmentation and phenotyping algorithm described above. At this threshold of 
detection, VSIG+/VIM+ cells represented a negligible population.  
Spatial and data analysis was performed using phenoptrReports (Akoya 
Biosciences), an R script package. Briefly, all single cell phenotype data was merged, 
aggregated and consolidated for each marker. Consolidated data was analyzed based 
on the phenotypes of interest. Using the XY coordinates of each cell, spatial relationships 
between cell types was visualized using the phenotrReports GUI. All data was graphed 
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using GraphPad Prism version 8.0.0 for Windows, GraphPad Software, San Diego, 
California USA, www.graphpad.com. 
Feature Barcoding Vector  
The feature barcode vector (LentiCRISPR-E-10xcs1) was built using the 
pLentiCRISPR-v2 (addgene: 52961) as the base vector.  All of the molecular 
modifications were performed by Epoch Life Sciences (Missouri City, Tx).  The 
pLentiCRISPR-v2 was modified to an optimized sgRNA scaffold73 that included the 3’ 10x 
capture sequence 1 
(cgtttCagagctaTCGTGgaaaCAGCAtagcaagttaaaataaggctagtccgttatcaacttgaaaaagtggca
ccgagtcggtgcGCTTTAAGGCCGGTCCTAGCAAtttttt); a ccdb bacterial expression 
cassette between the BsmBI restriction sites was introduced to reduce background during 
sgRNA cloning and library generation; and an N-terminal Flag-sv40 NLS was added to 
Sp. Cas9-nucleoplasmin NLS-P2A-Puro.   
Preparation of Feature Barcoded sgRNA Knockout Populations 
Lentiviral transductions of four separate feature barcode sgRNA vectors (targeting 
ABCG8, ILK, SMAD4 and ZEB1), were conducted on separate cell populations for both 
the PATC69 and PATC53 PDX lines. Lentivirus was concentrated through ultra-
centrifugation, resuspended in 200 µL of PBS, and stored at -80 °C until use. For each 
condition, 1x106 cells were transduced in 10 cm treated plates (Corning) using 8 µg/mL 
Polybrene (Sigma-Aldrich). Media was replaced after a 16-hour incubation, and each cell 
population was washed with PBS and then placed under Puromycin selection for 72 
hours. Following selection, all conditions were cultured for 22 days (or 10 days post 
“CRISPR Screen Injection point”) to match the in vitro CRISPR screen control-separation 
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profile at day 10. Prior to library preparation for scRNAseq, knockout populations were 
combined in equal proportion for each PDX line. Library preparation was conducted on a 
total of 10,000 cells per PDX line, resulting in an approximate coverage of 2500 cells per 
condition.   
sgRNA Phenotype Confirmation and Confirmation of Site-Specific Cutting  
Utilizing the same feature barcoded populations prepared for scRNAseq, 1500 
cells/well were seeded in triplicate in 12 well tissue culture plates (Corning) immediately 
following 72 hours of 2 µg/mL Puromycin selection. Cells were then cultured for a 
minimum of 10 doublings. Individual plates were then stained with 0.5% crystal violet (in 
25% methanol) for 2 hours. Plates were washed in water, dried overnight and then 
digitally scanned. After digitally scanning the plates, crystal violet was dissolved in equal 
volumes of 1% SDS, and 200 µL of each sample was moved into 96-well plates to 
measure absorbance at 570 nm. Relative growth was quantified based on the internal 
sgABCG8 negative control.  All data was graphed using GraphPad Prism v 8.0.   
Puromycin selected cells were collected for Sanger sequencing to confirm sgRNA 
induced indel formation relative to non-infected populations. Cell pellets for each sgRNA 
across both PATC69 and PATC53, 1x106 cells each, were isolated at Day 12 and Day 40 
for each PDX line (sgRPS27A indels representative at Day 12, all other sgRNAs at Day 
40). Cell pellets were centrifuged, washed once with PBS, and frozen at -80 °C. All Sanger 
sequenced regions were normalized against respective non-transduced PDX line 
populations, 1x106 cells/pellet. Primers for each cut site were developed to allow for 400 
- 800 bp products, and primer sites were run on 2% agarose gels and extracted following 
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amplification. Site-specific sequencing primers were utilized for Sanger sequencing, and 
indels distributions were calculated using the Synthego ICE Analysis Tool92. 
Computational Methods Development and Analyses 
As co-first author, Sanjana Srinivasan provided substantial computational support for this 
effort, enabling our findings. The manuscript is currently under review, and the methods 
are presented here with permission.  
The PDAC co-expression Network 
The PDAC co-expression network was generated by identifying genes with 
dynamic expression across the PDX cohort, and calculating spearman correlations 
across remaining gene pairs. In order to prune the network to prioritize biologically 
relevant gene pairs, a Bayesian framework developed by Yang, et al, Log Likelihood 
Score (lls), was applied93. The likelihood of correlation between any given gene-pair being 
functionally relevant is calculated comparing to the negative and positive gold standard 
gene pairs identified in this paper. Infomap94, a community detection tool for large 
networks, was used to cluster the network. For the resulting 31 clusters, the R package 
goseq95 was used to conduct hyper-enrichment analysis of Gene Ontology Biological 
Processes pathways on each cluster. To generate a cluster level enrichment score, we 
calculated a centroid score per cluster by taking the mean log-normalized expression of 
all genes in each cluster for each sample. A test was performed to quantify the difference 
in Cluster 1 enrichment across Classical and Basal models. The centroid scores for 
Cluster 1 and 23 were used to categorize the PDX models into three clusters using K-
means clustering. Clinical data from patients corresponding to the PDAC PDX cohort was 
provided by the lab of Dr. Eugene Koay96. Chi square tests were used to evaluate 
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differences between the cluster-defined Classical, Quasi-basal and Basal groups as well 
as the Moffitt binary classification. Cytoscape (version 3.7.2) was leveraged for 
visualization of both the PDAC co-expression network and STRING-anchored co-
dependency networks97,98. The PDAC co-expression network was visualized using a 
Prefuse Force-Directed Layout, with node color displayed based on Random Walk 
defined clusters and node size representative of Betweenness Centrality.  
TCGA Data 
We filtered the TCGA PDAC dataset to “high purity” samples annotated in the 
clinical data, where we obtained the Moffitt classification data99. Cluster centroids were 
calculated as described above with the PDXs and a k means of 3 was applied to the 
Cluster 1 and 23 centroid scores to categorize tumors into Classical, Quasi-basal and 
Basal. Tumor grade and differentiation status were obtained from the clinical data and 
Chi square tests were conducted to assess subtype level associations with the C1vC23 
signature and Moffitt groups. 
Low-Fat BAGEL 
Low-Fat BAGEL is an adapted framework of the BAGELv2100 algorithm to more 
accurately analyze small screens with limited training sets. The BAGEL and BAGELv2 
algorithms are previously described, and in short, calculate a “Bayes Factor”, a bayesian 
likelihood of any given gene being essential based on the distribution of the core essential 






Single Cell Analysis 
For the co-expression network normalization, we identified a subset of highly 
correlated genes per cluster and calculated a centroid score for each PCEN cluster by 




Chapter 3: RNAi-based functional characterization of a PDAC-prioritized cell 
surfaceome in vivo vs. in vitro 
 
This work is based on efforts outlined in our recent BioRxiv submission “Diversity Across 
the Pancreatic Ductal Adenocarcinoma Disease Spectrum Revealed by Network-
Anchored Functional Genomics” by Rose and Srinivasan, et al. (2020), DOI: 
https://doi.org/10.1101/2020.09.17.302034. As co-first author, Sanjana Srinivasan 
provided substantial computational support for this effort, enabling our findings. The 
manuscript is currently under review.  
3.1: Introduction 
Upon diagnosis, current clinical options for treatment of late-stage pancreatic 
cancer remain very limited, and provide only a marginal benefit to patient survival. The 
prominent KRAS-driven nature of pancreatic cancer, and the limited druggability of 
oncogenic KRASG12D, has been a major rate-limiting step in clinically addressing 
mitogenic signaling in this highly lethal disease. Effective KRAS inhibition has only 
recently begun to advance, starting with the KRASG12C inhibitors AMG 510 (Amgen) and 
MRTX849 (Mirati Therapeutics), and expanding into KRAS-SOS1 (Boehringer Ingelheim) 
and KRASG12D inhibitors (Mirati Therapeutics). As a result, druggable opportunities in 
PDAC have largely focused on targeting proteins involved in signaling both upstream and 
downstream of oncogenic KRAS. In an effort to curb downstream signaling, small-
molecule based inhibition of downstream of the mitogen-activated protein kinase (MAPK) 
and phosphoinositide 3-kinase (PI3K) pathways. Refined inhibitors have allowed for pan-
inhibition of multiple members in the PI3K pathway, however individual targeting of these 
downstream pathways has been met with combinatorial response, and dual inhibition 
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using selective MEK1/2 inhibition (selumetinib) and PI3K/AKT (MK-2206), showed no 
survival benefit and an increase in adverse effects when compared to mFOLFOX alone 
in gemcitabine-refractory patients with metastatic pancreatic cancer. Upstream targeting 
of the oncogenic KRAS pathway has largely been focused on monoclonal antibody-based 
targeting of receptor tyrosine kinase (RTK) EGFR, the only RTK-based therapy FDA-
approved for PDAC patients101. However, while approved, erlotinib-based EGFR 
targeted-therapy in PDAC only exhibited a marginal increase in survivability by two weeks 
in non-stratified setting101. Additionally, recent work in our lab has highlighted the need to 
inform combinatorial strategies based on the activation state of mitogenic drivers for 
individual tumors, as MEK1 inhibition alone leads to the activation of multiple RTKs (AXL, 
PDGFRα and HER1-2)102. These findings underscore the need to understand the 
activation state of putative oncogenic drivers on a patient-by-patient basis. Furthermore, 
there is a need to more comprehensively understand which receptors and downstream 
signaling pathways contribute to this compensatory signaling, and in what context they 
are relevant.  
Furthermore, even in settings where oncogenic mutant KRAS is genetically 
ablated in PDAC models, experimental findings have pointed towards the potential for 
acquired and inherent resistance. Constitutive AKT activation has been shown to bypass 
KRASG12D extinction itself103. Additionally, signaling through the YAP1/TEAD2 pathway 
has been shown to contribute to tumor relapse following KRAS extinction51. KRAS 
ablation in PDAC tumor populations has also revealed sub-populations that are KRAS 
independent, with experimental data pointing to enrichment in stemness-like properties, 
as well as an increased dependency on mitochondrial function52. As a result, even in the 
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event of a successful KRASG12D inhibitor, there is a need for a better understand the 
scope of PDAC oncogenic signaling heterogeneity across tumors, both in a KRAS-
dependent and KRAS-independent sense. In order begin to address this, we first sought 
to provide a deeper characterization of oncogenic signaling in PDAC starting from the 
extracellular face of the plasma membrane.   
Here, we pursued a logical and unbiased approach to establish a custom functional 
genomics platform in order to annotate PDAC-associated surface protein dependencies. 
Surface proteins provide direct insight into i) cellular architecture, ii) prominent signaling 
pathways, and subsequently iii) the potential dependencies of any cell type, including 
tumor cells. In addition to these proteins being therapeutically accessible and having the 
capacity to serve as biological markers for targets for drug delivery, charactering 
dependencies at the cell surface provides unique insight into the diverse oncogenic 
signaling “routes” that PDAC tumors can take.  
In order to apply a more prospectively refined approach, we defined a PDAC-
prioritized surface protein gene-set, hereon termed the PDAC “surfaceome”, which we 
utilized to establish a custom shRNA library for both human and mouse models. A 
multifaceted gene-set was derived from differential expression compared to matched 
normal-tissue, copy number amplification trends, and an in-house SILAC screen for 
KRASG12D dependency in iKras mouse cell lines35. In order to increase the potential for 
disease-relevance in our findings, we aimed to leverage early-passage PDAC PDX-
derived cell lines (PDX lines), and to model these tumors orthopically in the mouse 
pancreas during genetic screening. In addition, to better understand what insight 
modeling the tumor in vivo provides, we performed in vitro setting in parallel. This work 
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expanded on previous efforts in the lab whereby an in vivo functional genomics platform 
was established to identify epigenetic dependencies in human PDAC PDX-derived cell 
lines (PDX lines)104.  
Furthermore, in addition to the human PDX lines, the same three iKras mouse cell 
lines utilized for SILAC screening (AK192, AK196, and AK10965), were also optimized 
and applied for RNAi screening. The mouse screening library was built only using the 
SILAC data, and contributed towards a recent publication highlighting the role of SDC1 in 
mutant Kras-driven macropinocytosis35. For the purpose of this thesis, I will be focusing 
on the application of our human models, and subsequent findings.   
3.2: Results 
3.2.1: Establishment of a PDAC-prioritized Surfacome gene-set and custom shRNA 
library 
Expanding on our previous work in in vivo functional genomics platforms whereby 
small custom libraries were applied to inform on specific biological processes104, we 
utilized patient datasets and experimental data to prospectively prioritize a PDAC-
associated surface protein gene set, or PDAC surfaceome (See Methods). A multifaceted 
gene-set was derived from differential expression compared to matched normal-tissue, 
positive copy number vs. expression correlations, and an in-house SILAC screen for 
KRASG12D dependency in iKras mouse cell lines35 (Figure 1A - G). Each dataset 
provided a unique avenue for identifying PDAC-associated surface proteins of interest. 
For the copy number vs. expression dataset, a negative SMAD4 deletion was identified, 





























Figure 1: Establishing a PDAC-prioritized surfaceome gene-set. (a) Overview of 
PDAC surfaceome prioritization strategy, incorporating: i) matched-normal and laser 
microdissected tumor biopsy datasets to quantitatively rank tumor-specific 
overexpression, ii) copy-number amplification vs. RNA expression trends in Level 3 
TCGA data, and iii) KrasG12D surface protein localization though SILAC screening in three 
iKras mouse cell lines (AK192, AK196, and AK10965). (b) Volcano plot representation of 
PDAC-specific surfaceome overexpression, starting with establishing the original 
thresholds (top panels), refinement through confirmation of co-significance in both 
matched-normal datasets (middle panels), and secondary refinement through target co-
enrichment in a laser microdissected dataset (bottom panels). Comparison of gene 
matched-normal vs. stroma gene expression is also represented at each stage. Adjusted 
q-values calculated relative to the entire transcriptome available in each dataset. (c) 
Overview of SILAC screening strategy to identify proteins dependent on the expression 
of KrasG12D for localization to the extracellular face of the plasma membrane. (d - e) 
Overview of strategy to identify surface targets with positive significant copy-number vs. 
expression Spearman correlations within the TCGA dataset. Positive correlations 
implicate a potential oncogene while negative correlations implicate potential tumor 
suppressors. (f - g) Dot plots displaying examples of highly significant (MAL2) vs. non-
significant (SLC35F2), surface protein targets. (h) Correlations observed across the 
transcriptome recapitulate known copy number patterns in PDAC, including deletions and 
loss of expression in SMAD4 in early-stage epithelial tumors (highlighted in blue).  
3.2.2: Functional characterization of a PDAC-prioritized surfacome gene-set in 
early-passage PDX lines using parallel in vitro and in vivo RNAi screening  
Following prioritization of the PDAC surfaceome and construction of the library, 
shRNA screens were conducted on four early-passage PDX lines (PATC69, PATC124, 
PATC53 and PATC153). Prior to screening, the potential for each PDX line to maintain 
library coverage in vivo, following orthotopic transplant and tumor growth for 28 days, was 
confirmed using a 2.75K empty barcode library (Figure 2A).  Additionally, PDX lines 
selected for in vivo functional genomics encompassed both Classical (PATC69) and 
Basal-like (PATC124, PATC53 and PATC153) Moffitt subtypes, with PATC124 notably 
presenting a weaker expression of the Moffitt Basal-like gene-set comparatively (Figure 
2B). In addition, PATX69 and PATX124 tumors were isolated from primary tumors, while 
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PATX53 and PATC153 were isolated from liver metastases. These PDX lines also 
expressed a range of PDAC-associated mutations, with PATC153 notable expressing a 
mutation in PIK3CA and wild-type KRAS (Figure 2C). Early-passage PDX lines were 
transduced in vitro at 1000X coverage utilizing human surfaceome lentiviral library, and 
FACs analyzed to confirm a multiplicity of infection (MOI) of ≤ 0.3 for both empty barcode 
(RFP) and human surfaceome (GFP) libraries following an initial 16-hour transduction 
and additional 24 - 48 hours of culture. Following puromycin selection, each in vitro and 
in vivo screen replicate was established using 3x106 barcoded cells (1000X) for seeding 
treated tissue culture plates and orthotopic transplant into NSG mice, respectively (See 
Methods). For each model, we employed a parallel screening strategy to allow for direct 
comparison of in vitro and in vivo conditions, and collected screening populations across 
two time point at Day 14 and Day 28 (Figure 2D). For each time point, we collected at 


























Figure 2: Parallel in vitro and in vivo screening strategy for early-passage PDX 
lines. (a) Density plots representing distribution of the 2.75K empty barcode libraries 
before (Reference) and after in vivo implantation (vivo1 = Day 14, vivo2 = Day 28). (b) 
Schematic of parallel in vitro and in vivo RNAi screening strategy. Cells were transduced 
for 16 hours, media was replaced, and cells were incubated for an additional 24 - 48 hours 
to allow time for fluorescent protein expression. Percentage of transduced cells, 
distinguished by GFP expression in the human surfaceome library, were then quantified 
through flow cytometry (FACs) to confirm an appropriate MOI (≤ 0.3), and puromycin was 
introduced for selection. Immediately following 72 hours of puromycin selection, the 
Reference population was isolated (1000X coverage) was isolated, and replicate in vitro 
and in vivo screens were prepared (1000X coverage). (c) Common PDAC-associated 
mutations identified in each PDX line utilized for genetic screening.  
3.2.3: Quality control of parallel in vitro and in vivo RNAi screening data 
Upon completion of the parallel in vitro and in vivo screens for each PDX line, 
screen quality was heavily emphasized prior to data interpretation due to potential noise 
induced as a result of modeling these tumors orthotopically. To ensure quality of barcode 
dropout information from any in vitro or in vivo RNAi screen, we assessed three quality 
control metrics: i) successful library coverage, ii) fold-change separation between 
negative vs. positive controls, and iii) reproducibility of final barcode distributions across 
screening replicates. Library coverage for each screen, a fundamental requirement for 
potential control separation and screen reproducibility, was first confirmed at each time-
point relative to starting Reference populations (Figure 3A). Thus, ensuring that no in vivo 
screen elicited a major barcode population depletion, signified by a major left shift and 
increase in zero barcode counts in the density plots. These coverage errors are often a 
result of a lack of tumor engraftment following in vivo implantation, technical errors in 
tumor isolation during end point collection, or tumor necrosis. Following confirmation of 
complexity coverage, hairpin-level fold-change control separation between Negative 
(shLuc) and Positive (shRPL30 and shPSMA1) control gene-targets was observed at 
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each collection point (Figure 3B). Control separation between non-targeting shRNAs and 
shRNAs targeting housekeeping genes serves to quantitatively establish the range in 
dropout potential for each respective time-point. Finally, reproducibility across screen 
replicates was confirmed through Pearson correlation of paired barcode distributions 
(Figure 3C). A lack of reproducibility across replicates can be driven by external factors 

























Figure 3: Quality control of parallel in vitro and in vivo RNAi screening data. (a) 
Barcode readout count distribution (size normalized) of each in vitro and in vivo RNAi 
screen. (b) log2 fold-change separation of shRNAs targeting negative control Luciferase 
(non-targeting) vs. shRNAs targeting positive control PSMA4 and RPL30 (housekeeping 
genes). (c) Pairwise Pearson correlations of normalized barcode fold-change 
distributions for each RNAi screen.  
 
3.2.4: Parallel RNAi screens reveal in vivo and in vitro dependency enrichment, and 
characterizes both common dependencies and oncogenic signaling heterogeneity at 
the PDAC cell surface.   
We performed Redundant siRNA activity (RSA) analysis to rank surfaceome gene 
targets (logP) across PDX lines for both in vitro and in vivo screening conditions (Figure 
4A - D). Additionally, due to limitations with RNAi eliciting phenotypes in genes with low 
expression, and also to remove off-target artifacts, we matched RSA (logP) with RNA 
expression (TPM) on a model-by-model basis (Figure 4E - F). Parallel ranking of gene 
dropout provided insight into how tumor modeling can influence gene-target detection 
and ranking, and quantitatively characterized surfaceome hits that presented as in vitro 
specific, in vivo specific, and hits that scored in both contexts for four PDX lines. Notable 
trends include dropout of well-known oncogenic RTKs ERBB2 and ERBB3105 exclusively 
in vivo (in vivo p-value ≤ 0.01, in vitro p-value > 0.05), with ERBB2 knockdown exhibiting 
dropout in PATC69 and PATC53, and ERBB3 knockdown exhibiting dropout in PATC124 
(Figure 4A - D). Previous efforts have characterized aberrations in axon guidance 
signaling in PDAC based on exome sequencing and copy number analysis of a cohort of 
stage I and stage II tumor biopsies106. Prospective targets associated to axon guidance 
signaling were also functionally characterized in our RNAi surfaceome dataset.  
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Specifically, we identified the ephrin receptor RTK EPHB4 as a potential contributor to 
mitogenic signaling in PATC69, PATC53 and PATC153 (in vitro p-value ≤ 0.05, in vivo p-
value ≤ 0.05), and also identified a potential in vivo specific role for the semaphorin 
regulator SEMA4B in PATC69 (in vivo p-value ≤ 0.01, in vitro p-value > 0.05), the only 
Moffitt-defined classical model in the cohort (Figure 4A - D). In terms of distinguishing 
vulnerabilities based on Moffitt classification status (Figure 2B), we observed epithelial 
marker CDH1 dropout exclusivity in classical PATC69 (Figure 2B, Figure 4A). Supporting 
the previously described epithelial nature of the classical PDAC subtype10. In addition, we 
also observed integrins scoring in our Basal-like PDAC models, for ITGAV knockdown in 
PATC124, PATC53 and PATC153, and ITGB1 knockdown in PATC53 and PATC153 
(Figure 4A - D). Interestingly, these results have also highlighted novel and 
uncharacterized proteins as PDAC surfaceome protein dependencies, such as 
FAM171A2. While this target scored in vivo across all four PDX lines, it notably scored 
much more significantly in Basal-like PDXs derived from liver metastases (PATC53 and 
PATC153, p-value ≤ 0.01), implicating a potential role in epithelial-to-mesenchymal 
transition (EMT) or maintenance of metastatic tumors (Figure 4C - D). Model-specific and 
cross-model hits were further annotated through confirmation of RNA expression in order 
to ensure that no observed targets were an obvious byproduct of off-target effect (4E - F). 
Comprehensively, these findings highlight a significant heterogeneity in surface protein 
dependency across our human PDAC models (Figure 4G). This is highlighted by the fact 
that only five genes presented as significant hits across all four PDX lines (p-value ≤ 0.05) 
hits in vivo: ERBB2, ERBB3, ERBB4, CD109 and FAM171A2 (Figure 4G). Interestingly, 
along with providing an unbiased reaffirmation of the importance ERBB family in driving 
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mitogenic signaling in PDAC, this screening effort identified two novel surface protein 
targets for PDAC (CD109 and FAM171A2), and ultimately highlighted how genetic 
context and tumor-modeling context can influence the spectrum of surface protein 
























































































































































































































































































































PATC69 in vitro (Day 28)











































PATC69 in vivo (Day 28)














Figure 4: Parallel in vitro and in vivo RNAi screening results functionally 
characterize the PDAC-prioritized surfaceome. (a - d) Comparative plots illustrating 
parallel gene-level p-values, generated by RSA, of in vitro vs. in vivo screening conditions 
for PATC69 (a), PATC124 (b), PATC53 (c) and PATC153 (d). (e - f) Example plots of 
gene-level in vitro (e) and in vivo (f) PATC69 p-values (logP) vs. TPM normalized 
expression in in vitro and in vivo settings. (g) Venn diagram of RNAi defined gene targets 
(p ≤ 0.05), characterized in vivo. Cross-model hits are identified and paired with 
generalized protein function.  
3.2.4: Original validation of CD109 and characterization of potential downstream 
signaling pathways 
CD109 is GPI-anchored protein and is a member of the α2 macroglobulin/C3, C4, 
C5 family of cell surface regulators107. Originally identified in hematopoietic stem cells and 
activated T cells, this protein has been shown to be highly expressed in multiple 
cancers107. The role in CD109 in tumor progression has largely been attributed to its ability 
to bind to TGFβ1 and TGFβR1, resulting in the degradation of the receptor complex 
through caveolae-based internalization108. Along with regulation of TGFβ signaling, 
CD109 has been shown to play a role in pro-metastatic role in lung cancer models through 
EGFR-based STAT3 activation109. Finally, CD109 has been linked to tumor initiation and 
radio-resistance in GBM. Gene expression profiling in CD109 knockdown CD133-
/CD109+ cells highlighted YAP/TAZ signaling as a potential mechanism of action in the 
GBM setting. In addition, knockdown of CD109 resulted in destabilization of TAZ, 
implicating an upstream role in the pathway110. Overall, this data implicates CD109 as a 
multi-functional regulatory protein that likely contributes to tissue-specific and disease-
Note: This work was initially started alongside other target validation efforts, and was later continued 
with MennatAllah Shaheen to provide a foundation for her scientific training and her Master’s thesis. 
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specific roles, and while CD109 has previously been shown to be overexpression in 
PDAC111, the current functional role of this potential oncogene is unknown.  
Following the identification of CD109 as a potentially novel oncogene in PDAC, we 
next sought to validate the target, starting with shRNA-based knockdown and rescue 
experiments. We initially characterized the knockdown efficiency of multiple shRNAs and 
paired protein knockdown with colony formation assays (CFA). Relative to a non-targeting 
shRNA (shLuc-1) CD109 knockdown showed consistent CFA phenotypes across all four 
PDX lines, with non-effective shCD109-4 exhibiting limited colony depletion (Figure 5A - 
D). CFA phenotype did not correlate with protein levels of CD109 (Figure 5E). We next 
leveraged site-directed mutagenesis on vector containing a CD109 open-reading frame 
(ORF) in order to introduce synonymous mutations and subsequent resistance to 
shCD109-3, which was previously identified to elicit a phenotypic effect via colony 
formation (Figure 5F). We transduced PATC153 with vectors expressing GFP and the 
mutant CD109 ORF (CD109m), and compared colony formation following knockdown 
with the same shRNA set, which resulted in partial rescue of the CFA phenotype (Figure 
5G - H). In addition, we leveraged this partial rescue system to compare knockdown vs. 
overexpression of CD109, in shCD109-3 transduced PATC153 populations using RPPA. 
This resulted in an increase in phospho-YAP, Jagged1, total YAP and Src. 
Counterintuitively, these RPPA results implicate CD109 rescue in both increasing total 
YAP and blocking YAP signaling, although this increase in YAP phosphorylation may also 
be due to negative feedback signaling (Figure 5I). In addition, the increase in Jagged1 




 Along with exploring potential signaling pathways, we also sought to identify 
whether CD109 knockdown had an effect on cell cycle or apoptosis. When compared to 
the non-targeting control, a combination of BRDU labeling (in culture) and subsequent 7-
AAD DNA staining of fixed/permeabilized cells, 96 hours post-selection, highlighted an 
increase in cells in the G0/G1 phase following CD109 knockdown in both PATC124 and 
PATC153 (Figure 5J - K). This finding fall in line with an increase in phospho-Rb in CD109 
rescue/overexpression conditions (Figure I). In addition, concurrent Annexin-V and live 
cell permeability staining (by 7-AAD) did not show an increase in early or late-stage 
apoptosis for either PATC124 or PATC153 (Figure 5L - M). Here, a heat shocked cells 






















































Figure 5: Validation, rescue and characterization of novel target CD109. (a - d) 
Colony formation assays following shRNA-mediated knockdown of CD109 (shCD109-2, 
shCD109-3, shCD109-4), relative to a non-targeting control shRNA (shLuc-1). Matching 
western blots for each PDX line confirm CD109 knockdown efficiency. (e) Western blot 
for direct comparison of CD109 protein levels across PDX lines. (f) Sanger sequencing 
of mutated CD109 ORF (CD109m) following PCR mediated synonymous mutation at 
shCD109-3 binding site. (g) Knockdown and rescue colony formation assay in PATC153, 
included with matched western for protein knockdown and rescue validation. (h) Cell 
viability assay comparing knockdown and rescue of PATC153. (i) RPPA comparison of 
shCD109-3 transduced in PATC153 (GFP) vs. PATC153 (CD109m). Samples collected 
at 144 hours. (j - k) BRDU assay with 7AAD staining in PATC124 and PATC153, 96 hours 
following CD109 knockdown. (l - m) Annexin-V and cell permeability staining for early 
and late stage apoptosis signatures in PATC124 and PATC153 following CD109 
knockdown. Samples stained at 96 hours. Heat shock positive control included.  
3.3.5: Summary  
By establishing a utilizing a PDAC-prioritized surfaceome gene-set for custom 
library development, we applied parallel in vitro and in vivo RNAi screening to: i) elucidate 
oncogenic signaling heterogeneity at the cell surface in pancreatic tumors, ii) recapitulate 
previously annotated oncogenic drivers, and iii) identify new novel surface proteins as 
potential oncogenes. Optimization of in vivo screening conditions, through the use of a 
2.75K empty barcode library, and subsequent confirmation of data quality based on 
library, control separation, and screen replicate reproducibility, aided in established an 
unbiased dataset ranking surface proteins across four PDX lines. By performing RSA on 
parallel in vitro and in vivo screen shRNA dropout datasets, we identified differential 
ranking between the two platforms, highlighting the effect of tumor modeling on genetic 
screening, and furthermore identifying multiple in vivo and in vitro specific targets on a 
model-by-model basis. Common targets across all four PDX lines identified the ERBB 
family as a consistent driver of mitogenic signaling in PDAC tumors, while also identifying 
novel targets such as CD109 and FAM171A2. Upon further evaluation, we validated 
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CD109 as an oncogenic driver in PDAC, while also providing preliminary information on 
potential signaling through the Hippo and Notch pathways. We also confirmed that growth 
inhibition in CD109 occurs through disruption of the cell cycle, and not through apoptosis. 
Importantly, along with identifying and characterizing individual targets of interest, this 
initial RNAi-based work quantitatively highlighted the high level of heterogeneity of 




Chapter 4: Parallel in vivo vs. in vitro CRISPR functional genomics platform to 
establish “top-down” PDAC dependency networks 
 
This work is based on efforts outlined in our recent BioRxiv submission “Diversity Across 
the Pancreatic Ductal Adenocarcinoma Disease Spectrum Revealed by Network-
Anchored Functional Genomics” by Rose and Srinivasan, et al. (2020), DOI: 
https://doi.org/10.1101/2020.09.17.302034. As co-first author, Sanjana Srinivasan 
provided substantial computational support for this effort, enabling our findings. The 
manuscript is currently under review.  
4.1: Introduction 
Previously, our efforts in utilizing RNAi to inform on a PDAC-prioritized surfaceome 
aided in capturing the effect of in vivo modeling on target identification and identifying 
novel targets. However, in addition to informing on individual targets, this effort also 
provided a quantitative characterization of oncogenic signaling heterogeneity at the cell 
surface in pancreatic cancer. However, while the original RNAi screens provided a 
foundational dataset of functional and PDAC-relevant surface proteins, and aided in 
identifying multiple novel and accessible avenues for targeting pancreatic tumors, these 
were not sufficient to inform on the underlying drivers of this heterogeneity. As a result, 
many model-specific hits identified in the original RNAi work do not have enough context 
to be applied to larger cohorts, and even targets that score across all available models 
do not necessarily apply to the PDAC disease spectrum as a whole. 
Here, we sought to expand on our original findings and address the heterogeneity 
observed in our RNAi screens by applying a network-based approach to expand on the 
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functionally-refined surfaceome gene set. We incorporated CRISPR-Cas9 into our in vivo 
functional genomics platform, and incorporated the STRING network to expand on likely 
protein-protein interactions (ppi) of the original functionally-annotated surfaceome for 
library development. CRISPR-Cas9 served as a more stringent platform with less off-
target potential due to requirement of a protospacer adjacent motif (PAM) for sgRNA 
cutting, allowing for more gene targets within the same library complexity (4 sgRNAs vs. 
10 shRNAs per gene). Additionally, this allowed for an increase in the number of controls 
within the library, which included established essential (50) and non-essential (50) gene-
sets90,112. Incorporating these essential and non-essential gene-sets within the library 
allowed for Bayesian analysis (BAGEL) of sgRNA dropout and an independent 
assignment of a likelihood-ratio for each gene target. This is in contrast to RSA, which 
provided hypergeometric p-values at the gene level based on the relative ranking of gene-
associated shRNA dropout113.  
As a result of these modifications, we hypothesized that integrating i) a “top-
down” network-informed custom library with ii) a CRISPR-based in vivo functional 
genomics approach, would allow for a deeper characterization of the genetic 
drivers of oncogenic heterogeneity within our PDX lines. Utilizing this approach, we 
assigned STRING-anchored dependency networks for each PDX model, as oppose to 
only ranking targets and applying a single-gene focus114. Merging these PDX-line 
dependency networks around common nodes served to inform on oncogenic patterns 
along the Classical to Basal-like spectrum of PDX lines. In addition, we sought to validate 
in vivo specificity and prominent network-defined signatures observed within the CRISPR 
dataset. To validate in vivo-specific and model-specific targets that scored across both 
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RNAi and CRISPR systems, we applied parallel in vivo vs. in vitro competition assays 
with barcoded vectors. In addition, we leveraged pharmacological agents to orthogonally 
validate prominent RTK-focused gene perturbation phenotypes. Ultimately, this 
integrated network-centric approach for custom library development served to inform on 
potential drivers of oncogenic signaling heterogeneity, and provided a “top-down” 
approach” to characterize these PDX lines based on interconnected dependencies.  
4.2: Results 
4.2.1: Custom “top-down” in vivo CRISPR screening strategy  
To further annotate and expand on the RNAi-refined PDAC-prioritized surfaceome, 
we integrated a stringent STRING network (PPI score ≥ 0.80) to annotate and expand on 
100 surface proteins defined (RSA ≤ 0.05 and FC < -2) in the in vivo RNAi screens (Figure 
6A, CRISPR modifications). The sgRNA sequences selected for screening were 
synthesized based on the Brunello library115, pooled, cloned into a pRSG16-U6-sg-
HTS6C-UbiC-TagRFP-2A-Puro lentiviral vector, and paired with unique 18 nucleotide 
barcodes (Cellecta). The CRISPR screening protocol was modified for the in vivo setting, 
allowing for limited cutting prior to implantation in order to address differences in doubling 
rate, and DNA accessibility, between cells in the tumor core vs. the outer edge. To this 
end, along with an initial Reference collection (1000X) following MOI confirmation and 
puromycin selection (See Methods), cells were kept in in vitro for an additional 12 Days 
and a secondary implantation Reference (1000X) was collected (Figure 6B). Cells were 
also plated for in vitro screening at the time of implantation, and were collected as a time-
course to track non-essential vs. essential separation in control populations. For each 
PDX line, the original Reference populations was utilized for determining sgRNA-level 
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fold-change (Figure 6B). Integrating a more refined method of gene perturbation and 
dropout analysis with a network-informed custom library built upon the previous 
annotation of a PDAC surfaceome, and enabled us to established ppi-anchored networks 
of dependency for each PDX line for both in vitro and in vivo settings. Thus, this network-
anchored methodology allowed for in vivo tumor modeling while also leveraging 
protein-protein interaction scores to inform on the spectrum of characterized 



























Figure 6: Overview of “top-down” screening strategy and parallel in vitro vs. in vivo 
screening methodology.  (a) Overview of “top-down” functional genomics approach 
utilizing human PDX lines. RNAi-defined hits derived from a PDAC-prioritized cell 
surfaceome gene set is annotated and expanded on using a custom STRING-based 
CRISPR library. (b) Parallel in vitro vs. in vivo screening methodology for RNAi and 




4.2.2: Quality control of parallel in vitro and in vivo CRISPR screening through Low-
Fat BAGEL analysis  
In similar fashion to the RNAi screens discussed in Chapter 3, data quality was 
heavily emphasized prior to interpretation of parallel in vitro and in vivo CRISPR screening 
results. First, library complexity coverage and reproducibility across screening replicates 
was confirmed for each collection point (Figure 7A - B).  
We then applied a modified version of BAGEL (Bayesian Analysis of Gene 
EssentiaLity), a supervised learning method that: i) accesses screen quality by comparing 
separation and relevant classification of an internal set of essential vs. non-essential gene 
populations, and ii) calculates a “Bayes Factor” for each gene target in the library, a 
likelihood-ratio of any gene being assigned as essential, based on the distribution of 
internal essential vs. non-essential gene populations90,112. Specifically, we developed and 
applied Low-Fat BAGEL for the optimized analysis of small custom libraries with limited 
training sets. For each PDX line in vitro time-course collection point, increasing log2 fold-
change separation was observed between essential and non-essential gene knockout 
populations, as well as at the in vivo end point (Figure 7C). In addition, screen 
performance was accessed through the calculation of precision-recall curves of the 


























Figure 7: Quality control of parallel in vitro and in vivo CRISPR screening through 
Low-Fat BAGEL analysis. (a) Normalized barcode read distribution (CPM) for each in 
vitro and in vivo CRISPR screen collection point. (b) Pairwise Pearson correlations across 
screen replicates for CRISPR screens performed utilizing PATC69 (left), PATC124 
(middle) and PATC53 (right). (c) Density plots of essential and non-essential guide-level 
log2 fold change dropout for PATC69 (top), PATC124 (middle), and PATC53 (bottom), 
for in vitro time-course collection end points and in vivo end point. (d) Combined precision-
recall curves, based on Low-Fat BAGEL analysis of PATC69 (top), PATC124 (middle), 
and PATC53 (bottom).  
 
4.2.3: Dependency networks inform on common and unique CRISPR-defined 
vulnerability trends across in vivo and in vitro contexts  
Following assignment of gene-level Bayes Factors to each gene target in the 
CRISPR library, BFs were quantile normalized and utilized to compare gene essentiality 
(BF > 1) across the three available PDX models (PATC69, PATC124 and PATC53) in 
both in vitro and in vivo settings. Dependencies across the PDX lines were highly diverse, 
with Basal-like PATC53 exhibiting the most unique dependencies both in vitro and in vivo 
(Figure 8A - B). Furthermore, the only shared vulnerabilties across all models and in vitro 
and in vivo contexts being ribosome-associated RACK1 and RPL30, as well as the MYC 
proto-oncogene (Figure 8A - B).  In addition to common hits, additional trends in PDX 
dependencies serbed to corroborate our PDX model sysemts. Specifically, the BF trends 
in SMAD4 knockout, ranging from non-essential in epithelial primary tumor PATC69 to 
highly-essential in mesenchymal liver metastasis PATC53, recapitultes known dual 
supressive and oncogenic features of TGFβ signaling in tumors exhibiting differing levels 
of transdifferentiation. We next sought to further infrom on the diversity of BF-defined hits 
across these PDX lines by integrating these gene-level likelyhood-ratios within the 
underlying STRING-network that informed the sgRNA library. Furthermore, these 
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STRING-anchored dependency networks were merged based on overlapping essentiality 
thresholds (BF >1), and displayed using a force-directed layout in order to visualize ppi 
interconnectivity of observed dependencies for both in vivo (Figure 8C - E) and in vitro 
(Figure 8F - H) contexts. Notably, the PATC53 dependency networks displayed a unique 
shift away from the semi-overlapping dependencies observed in PATC69 and PATC53 
(Figure 8E, 8H), despite the fact that both PATC53 and PATC124 both Moffitt-defined as 
Basal-like (Figure 2B). The interconnected vulnerabilities uniquely identified in PATC53 
were found to be associated with multiple biological signaling contexts, including: 
epithelial-to-mesenchymal transition (EMT) (e.g. SNAI1, ZEB1, SMAD4, MAPK11 and 
MAPK14), intracellular signaling kinases (e.g. BCAR1, NCK1, CRKL and CRK), heparan 
sulfate proteoglycan regulation (e.g. SDC3 and EXT1), integrin signaling (e.g. ILK, ITGB1, 
ITGB2 and NPNT), and cell junction regulation (e.g. CTTN, TJP1 and TJP2), and (Figure 
8C - H). 
In addition to the clear dependency spectrum shift in PATC53, we also observed 
a unique RTK bias and EGFR dependency in PATC124 (Figure 8D, 8G). We applied 
pharmacological inhibition of EGFR for orthogonal confirmation of this unique 
dependency. Dose response comparison across PDX lines utilizing Gifitinib and 
Osimertinib identified relative PATC124 sensitivity to EGFR inhibitors compared to 
PATC53 and PATC69 (Figure 9A - B). The dose response endpoint for each PDX line 
was normalized by doubling time (Figure 9C). Immunohistochemistry (IHC) staining 
identified the presence of phosphorylated EGFR in both PATC69 and PATC124 
secondary transplant tumors, but not in PATC53 tumors (Figure 9D). Implicating that 
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Figure 8: Leveraging STRING-informed CRISPR libraries to establish and merge 
dependency maps across PDXs in both in vivo and in vitro contexts. (a) Venn 
diagram of functional targets derived from in vivo orthotopic CRISPR screening of PDX 
lines using a quantile-normalized Bayes factor (BF) > 1. (b) Venn diagram of functional 
targets derived from in vitro CRISPR screening of PDX lines using a quantile-normalized 
Bayes factor (BF) > 1. (c - e) CRISPR in vivo screening results from PATC69 (c), 
PATC124 (d), and PATC53 (e) PDX lines overlaid onto a merged PPI force-directed 
diagram. The BF of each gene indicates the degree of vulnerability of the gene, with BF 
> 1 indicating an essential gene. (f - h) CRISPR in vitro screening results from PATC69 
(f), PATC124 (g), and PATC53 (h) PDX lines overlaid onto a merged PPI force-directed 
diagram. The BF of each gene indicates the degree of vulnerability of the gene, with BF 

















Figure 9: Orthogonal validation of CRISPR-defined EGFR dependency in PATC124 
through pharmacological inhibition in vitro. (a) Dose-response curve displaying 
relative (vehicle normalized) viability vs. increasing concentrations of Gefitinib for 
PATC69, PATC124 and PATC53 in vitro. (b) Dose-response curve displaying relative 
(vehicle normalized) viability vs. increasing concentrations of Osimertinib for PATC69, 
PATC124 and PATC53 in vitro. (c) Timing of dose-response end-point collection 
normalized at three PDX doublings in vitro. (d) Immunohistochemistry staining for pAKT 







4.2.4: Development of barcoded sgRNA completion assays for validation of in vivo 
specific targets  
As previously described here and in Chapter 3, parallel in vitro vs. in vivo screening 
efforts utilizing custom RNAi and CRISPR libraries identified gene targets that scored 
exclusively in vivo. In an effort to validate the in vivo-specific context of these 
dependencies, we sought to establish a cost-effective competition assay protocol for the 
comparison of non-targeting control vs. target knockout populations using a barcode-
based strategy. Specifically, for both non-targeting and target knockout transduction, we 
leveraged bicistronic sgRNA lentiviral vectors paired with unique barcodes not 
represented in our custom human and mouse libraries (Figure 10A). In both RNAi and 
CRISPR settings, we identified SEMA4B as an in vivo specific dependency of PATC69, 
(Figure 10B - C). While the role of SEMA4B in PDAC is not known, it was original identified 
as playing a role in axon guidance116 and has been shown to play a role in limiting cell 
motility in lung cancer cell lines117. Prior to running the competition assay, we compared 
SEMA4B knockout across multiple bicistronic sgRNA vectors, verifying knockout in 
vectors 2 and 3 (Figure 10D). For this experiment, we utilized sgRNA vector 3 (Figure 
10D). To perform the competition assay, we separately transduced two PATC69 PDX line 
populations in vitro with the non-targeting vector and sgSEMA4B-3, and confirmed MOI 
< 0.3 for both populations to ensure comparable vector integrations for each setting. We 
then combined both populations at a 50:50 ratio and isolated a subset to serve as an 
initial Reference. The mixed population was then split into in vitro and in vivo growth 
conditions, with tumor cell implanted, maintained and collected to match in vitro and in 
vivo CRISPR screening conditions. Upon collection, nested PCR was utilized for barcode 
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isolation and multiplexing in preparation for sequencing. Compared to the Reference 
population, in vitro culture did not have an influence on the ratio of non-targeting vs. 
SEMA4B targeting barcodes, however there was consistent relative reduction in SEMA4B 
following tumor growth in vivo (Figure 10E). As a result, we identified SEMA4B as a 
PATC69-specific in vivo dependency. Due to the low complexity of the sample and unique 
barcode signatures representing these bicistronic sgRNA integrations, these multiplexed 
samples were easily spiked into other larger library sequencing efforts, allowing for a cost-
effective validation methodology. By quantifying relative barcode abundance rather than 
fluorescent metrics, implanted tumors did not need to be dissociated for FACS analysis, 
avoiding potential noise due to autofluorescence. This methodology served as an 























































PATC69 sgSurfaceome CRISPR Screen Comparison












































































































Figure 10: Barcoded in vitro vs. in vivo competition assay validated in vivo-specific 
SEMA4B dropout in PATC69. (a) Overview of sgRNA knockout competition assay 
comparing negative control vs. target-knockout barcode populations following tumor 
growth in in vitro and in vivo settings. (b) Parallel RNAi screening results for PATC69 
highlighting SEMA4B as an in vivo specific target. (c) Parallel CRISPR screening results 
for PATC69 highlighting SEMA4B as an in vivo specific target. (d) Western blot comparing 
SEMA4B protein expression following transduction of negative control and SEMA4B 
targeting sgRNAs (bicistronic vectors). (e) Negative control vs. SEMA4B knockout 
barcode population comparison following in vitro and in vivo tumor growth conditions.  
 
4.2.5: Summary  
Here, we developed and applied STRING-informed in vivo CRISPR screening 
platform to expand on the heterogeneity of RNAi-defined surface proteins observed in 
Chapter 3. Performing in vivo genetic screening utilizing CRISPR-Cas9 required 
developing and implementing several updated experimental and analytical protocols. We 
modified our in vivo functional screening protocol to adjust for the wider range of sgRNA 
mediated indel formation compared to shRNA knockdown. In addition, in order to apply 
BAGEL analysis on our small custom sgRNA library, we implemented an updated version 
of BAGEL, termed Low-Fat BAGEL, to access screen quality and to calculate the 
likelihood of essentiality for each gene in the library, based on the distribution of essential 
(50) and non-essential (50) genes. Following confirmation of screen quality, we integrated 
these likelihood-ratios, or Bayes factors, with the same STRING ppi network that served 
as the foundation for the custom sgRNA library. In doing do, we constructed dependency 
networks for each PDX model and merged these networks based on common nodes, 
allowing for a more comprehensive characterization of these dependency spectrums as 
compared to a single-gene focus. Here, we identified a clear dependency shift in PATC53 
away from PATC124 and PATC69. These dependencies associated to multiple biological 
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processes present in mesenchymal cells, including EMT and integrin-based signaling. In 
order to further verify the vulnerability trends observed in the data, we provided an 
orthogonal validation of the PATC124-speficic EGFR dependency using pharmacological 
inhibitors. Finally, in an effort to highlight that in vivo specificity we observed in our genetic 
screens was not simply an artifact, we developed a simple competition-based platform to 




Chapter 5: Integration of PDAC co-expression network and in vivo functional 
genomics provides dependency-context and identifies intratumoral axes of 
vulnerability 
 
This work is based on efforts outlined in our recent BioRxiv submission “Diversity Across 
the Pancreatic Ductal Adenocarcinoma Disease Spectrum Revealed by Network-
Anchored Functional Genomics” by Rose and Srinivasan, et al. (2020), DOI: 
https://doi.org/10.1101/2020.09.17.302034. As co-first author, Sanjana Srinivasan 
provided substantial computational support for this effort, enabling our findings. The 
manuscript is currently under review.  
5.1: Introduction 
Our previous efforts in leveraging a “top-down” in vivo functional genomics 
approach served to inform on PDAC signaling heterogeneity within our available PDX 
lines. While leveraging a ppi network to inform on sgRNA library construction provides a 
degree of signaling context for established genes, and subsequently allows for a more 
comprehensive comparison of dependency spectrums across available models, these 
findings are still fundamentally limited by model availability. We next sought to establish 
a platform that would allow us to anchor these model-specific dependency spectrums 
within the larger context of PDAC diversity.  
Recent efforts in PDAC molecular characterization have begun to expand on 
clinically-associated transcriptomic signatures in order to classify these tumors into 
subtypes11. Of these, the most widely accepted PDAC subtyping method is the Moffitt 
classification, which distinguishes PDAC into “classical” and “basal-like” cohorts10-13. 
However, while this transcriptomic-based classification serves to aid in predicting patient 
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prognosis, it does not provide a means to help predict response to targeted therapy or 
genetic perturbation. Moreover, therapeutic intervention, as well as subclonal evolution, 
have been shown to influence these subtype classification12. This underscores the 
relevance of intratumoral composition underlying these bulk subtype signatures, as these 
findings suggest that the intertumoral heterogeneity in dependencies that we previously 
observed across PDX lines likely extends to the subclonal composition of these tumors.  
Here we sought to establish a platform in order to: i) quantitatively capture gene 
signatures underlying disease diversity in PDAC, and ii) anchor genetic dependencies 
within these diversity-driving signatures. To this end, we developed a systematic 
approach to correlate the status of gene-cluster activation with response to targeted gene 
perturbations. First, we established a tumor-specific co-expression network derived from 
the same curated cohort of PDXs where we derived our PDX lines. The co-expression 
network was then refined and GO annotated, resulting in 31 defined gene clusters. We 
observed two prominent anti-correlating cluster signatures within this PDAC co-
expression network (PCEN), with one of signatures recapitulating Moffitt classical and 
basal-like molecular subtypes on a continuous scale. In addition, this differential signature 
was recapitulated in TCGA samples, and significantly associated to PDAC clinical 
features (tumor grade, site of metastatic reoccurrence) in both the PDX and TCGA 
datasets. Importantly, was also recapitulated this spectrum within individual PDX lines 
through single-cell RNA sequencing (scRNAseq).  
We next leveraged the PCEN to allow us to quantitatively delineate vulnerability 
context within this high-resolution map of transcriptomic diversity. By anchoring CRISPR-
defined genetic dependencies within these clinical annotated differential cluster 
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signatures, we were able to inform on molecular context underlying these PDX-specific 
vulnerabilities. Finally, we employed a CRISPR-based feature barcoding strategy to 
validate the context-specificity of cluster anchored targets intratumorally, while also 
introducing a strategy to observe how informed genetic perturbations can influence 
intratumoral heterogeneity, rather than just bulk tumor size. 
Overall, this work presents a novel and quantitative approach to stratify genetic 
targets within the context of transcriptomic signatures underlying pancreatic tumor 
diversity, representing a critical advancement towards the development and positions of 
subtype-specific targeted therapies in PDAC.  
5.2: Results 
5.2.1: Defining Transcriptomic Diversity in PDAC through the Construction and 
Annotation of a PDX-based Co-Expression Network 
In order to assess the diversity of the cell-intrinsic transcriptomic signatures 
specific to PDAC tumors, we leveraged early passage PDAC PDXs in order to maintain 
the cellular heterogeneity of tumor lesions while reducing the contribution of the stromal 
components prevalent in these tumors118 (Figure 11A). Whole-transcriptome sequencing 
was conducted to annotate a set of 48 PDAC PDX tumors curated at MD Anderson. As 
described in Chapter 3, we recognized a level of transcriptional diversity within this cohort 
consistent with the previously defined Moffitt-classification status and distribution of 
classical and basal-like PDAC (Figure 2B, Figure 11A). Additionally, we conducted whole-
exome sequencing and confirmed mutation frequencies comparable to those reported by 
the TCGA (Figure 11B).  
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We then calculated global pairwise Pearson correlations of genes with variable 
expression to quantify concordant patterns of transcriptomic diversity across our models. 
These correlations were further pruned to prioritize biologically relevant gene pairs93, 
resulting in a PDAC co-expression network (PCEN) consisting of 103,000 correlations of 
7,828 genes (Figure 11A). Paired mutation profiles for each PDX line were also annotated 
incorporated for analysis (Figure 11B). Using InfoMap, we divided the co-expression 
network into 31 clusters, which were further genome ontology (GO) annotated (Figure 
11C). PDAC diversity was then quantified by applying a dimensional reduction approach 
on our 31 defined clusters. Specifically, we quantified the mean expression of each 
cluster, or centroid score, on a tumor-by-tumor basis, for all 48 PDX models in the PDAC 
cohort. To determine if the mutational background of a model was significantly associated 
with cluster enrichment across the PDX cohort, we applied UNCOVER to identify 
complementary patterns of mutation enrichment across groups.  
We observed general anti-correlative cluster expression patterns across the PDAC 
PDX cohort, which were reflected in cluster positioning and subsequent cross-cluster 
connectivity. The most significant anti-correlating signatures were identified in clusters 
predominantly localized to adjacent ends of the force-directed layout (Figure 11D - F). 
The non-overlap of these adjacent anti-correlating cluster trends implicates multiple 
distinct molecular signaling contexts contributing to diversity across the PDAC disease 
spectrum (Figure 11D - F). The top anti-correlative signatures were quantified between 
two opposing clusters: Cluster 1 vs. Cluster 23, respectively enriched for lipid metabolism 
vs. cell development; and Cluster 2 vs. Cluster 13, respectively enriched for Golgi-vesicle 
transport vs. nuclear-transcribed mRNA catabolism (Figure 11E - F). In addition, the 
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PCEN also highlighted GO annotated clusters critical for proliferating tumor cells, 
specifically Cluster 15, cell cycle, and Cluster 16, mitochondrial transport and organization 
(Figure 11C).  
These findings reveal that, along with 31 distinct gene clusters, two distinct anti-
correlating cluster signatures contribute to PDAC tumor diversity and have the potential 






























Figure 11: Defining Signaling Diversity in PDAC through the Construction and 
Annotation of a PDX-based Co-Expression Network. (a) Overview outlining the 
development of the PDAC co-expression network from a diverse and representative 
PDAC patient-derived xenograft (PDX) cohort of 48 models, and subsequent integration 
of mutation data for cluster enrichment analysis. (b) Oncoplot of common PDAC-
associated mutations in the 48 model PDX cohort displays mutation frequencies similar 
to previous publications. (c) Force-directed layout of the PCEN. Gene clusters, defined 
by Gene Ontology (GO), visually highlight nodes with a minimum of 12 edges. (d) Heat 
map depicting Pearson correlations between cluster centroid scores across 48 PDX 
models. Starred correlations represent an adjusted p-value < 0.05. (e) Force-directed 
layout of the PCEN (top) and matching GO hierarchical treemaps (bottom) of prominent 
anti-correlative cluster centroid trends across the PDAC co-expression network 
highlighting Cluster 1 (Lipid metabolism) vs. Cluster 23 (Cell development). (f) Force-
directed layout of the PCEN (top) and matching GO hierarchical treemaps (bottom) of 
prominent anti-correlative cluster centroid trends across PDAC co-expression network 
highlighting Cluster 2 (Golgi vesicle transport) vs. Cluster 13 (mRNA catabolism). 
 
5.2.2: Network integrtion identified EMT-assoicated dependencies along prominent 
PDAC molecular signatures  
To anchor these vulnerability trends within the landscape of PDAC diversity, we 
then integrated the CRISPR-screen defined dependencies within our co-expression 
network (Figure 12A). The integration displayed a clear shift in the PATC53-associated 
dependency spectrum along the Cluster 1 -to- Cluster 23 axis, with many of the 
dependencies identified in the CRISPR screen localized within, or adjacent to, Cluster 23 
(Figure 11D, Figure 12 B - D). Specifically, MAPK11 and FAM171A2 were localized within 
Cluster 23 itself, NKAIN4 in Cluster 25, and SMAD4, ZEB1 and SDC3 in Cluster 31 
(Figure 11D, Figure 12 B - D). The network localization of functionally annotated and 
PATC53-specific ZEB1, an EMT-associated transcription factor, and SMAD4, an EMT 
facilitator and oncogenic driver in advanced PDAC, implicated a connection between the 
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Figure 12: Informed CRISPR characterization of PDX models identifies co-
expression network cluster-associated functional diversity within the PDAC 
cohort. (a) Overview of integration of parallel PCEN and functional genomics platforms 
for the identification of cluster-anchored vulnerabilities for representative, and in vivo 
modeled, PDX lines. (b - d) CRISPR in vivo screening results from PATC69 (c), PATC124 
(d), and PATC53 (e) PDX lines overlaid onto a merged PPI force-directed diagram. The 
BF of each gene indicates the degree of vulnerability of the gene, with BF > 1 indicating 
an essential gene. 
 
5.2.3: Prominent anti-correlating cluster signatures outline a continuous classical-to-
basal differential signature  
The distinct gene clusters we identified in the PDAC co-expression network 
provide a means to deeply characterize any PDAC model by considering correlations in 
cluster enrichment patterns, an orthogonal strategy to current approaches that use 
consensus clustering to assign a tumor subtype based on refined PDAC-specific gene 
sets. Leveraging our functional genomics platform, we previously observed a clear 
dependency shift along the Cluster 23 in the basal-like PATC53 (Figure 12D). We also 
noted a strong anti-correlative trend between the Cluster 1 and Cluster 23 centroid scores 
among the entire PDAC PDX cohort (Figure 11E). Upon further characterization, we 
observed Cluster 1 centroid scores across our PDX cohort showed low variance among 
Moffitt-defined classical models, but a wider range and significant depletion of Cluster 1 
gene expression (p = 3.67 x 10-6) was observed in basal-like models (Figure 13A). 
Interestingly, Cluster 1 unbiasedly localized the entire set of 21 classical signature genes 
from the Moffitt classification. Together, these findings suggested that we could leverage 
the anti-correlating C1vC23 axis as a classical to basal-like differential signature. Indeed, 
by applying K means clustering on only the Cluster 1 and Cluster 23 centroid scores, we 
separated the PDX cohort into three groups: i) enrichment in Cluster 1 represented 
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Moffitt-defined classical models, ii) enrichment in Cluster 23 represented Moffitt-defined 
basal-like models, and iii) models with partial enrichment of both Clusters 1 and 23, which 
we termed “quasi-basal” (Figures 13B - D). Thus, our C1vC23 signature provides a 
continuous transcriptomic signature that expands on the original binary Moffitt 
classification and uncovers a transitionary quasi-basal phenotype of PDAC.  
To gain further insight into the molecular signatures this continuous signature, we 
conducted gene-set enrichment analysis to compare CoDEX-defined classical vs. basal-
like models within our PDX cohort. This highlighted that EMT signaling was significantly 
enriched among PDX models that fell into the CoDEX definition of basal-like, whereas 
this gene set was depleted in classical models (Figure 13E). Enrichment of an EMT 
signature in basal-like PDX models supports the hypothesis that the basal-like subtype is 
strongly associated with tumors where a majority of tumor cells has at least partly 
undergone transdifferentiation towards a mesenchymal phenotype. Consistently, analysis 
of clinical and histological data (See Methods) for the PDX cohort demonstrated that 
basal-like tumors were uniformly associated with poor differentiation status and distant 
metastatic recurrence (Figure 13B). Next, using high epithelial content PDAC patient data 
from TCGA (30% - 80% epithelial cells), we confirmed the presence of the network-
derived subtyping, again identifying a quasi-basal continuum. Furthermore, we 
recapitulated the association between tumor histology and the network-derived subtype 
in the TCGA dataset, wherein more poorly differentiated tumors were classified as basal-
like, with strong enrichment in Cluster 23 gene expression (Figure 13F). By quantitatively 
characterizing a quasi-basal population, the CoDEX platform enables a more precise 
definition of the clinically relevant basal-like tumor cohort while also expanding on 
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associated molecular dependencies that may be considered for therapeutic intervention. 
Moreover, CoDEX defines a broader, cluster-level characterization of the range of 
molecular signaling contributing to diversity in PDAC, which can be used to granularly 
ascertain pathways that may be therapeutically targeted to exert anti-tumor effects across 





































Figure 13: Prominent anti-correlating CoDEX clusters recapitulate a granular 
spectrum of “classical”, “quasi-basal”, and “basal-like” cells intertumorally. (a) Box 
plot of average Cluster 1 centroid score across Moffitt defined classical and basal-like 
models. Box-whisker plots show median ± first and third quartiles. P values are derived 
from t–test (n = 48 PDX tumors). (b) Overlay of the normalized expression score of each 
gene over the PDAC co-expression network of CoDEX defined classical, quasi-basal and 
basal models (left panel). Pie chart comparison of clinical histology and recurrence of 
patients associated with PDX models across subtypes. P values are derived from Chi 
Square test (middle panel). Heat map of C1vC23 anti-correlating cluster signature 
differential and matching Moffitt classification (right panel). (c) K means clustering reveals 
optimal k=3 using the Cluster 1 and Cluster 23 centroid scores across the PDX models 
paired with Consensus Clustering (k=2) into Moffitt’s classical and basal subtypes. (d) 
PCA demonstrating the PCEN derived subtypes with the quasi-basal group in driving the 
PCs compared to the binary Moffitt Classification. (e) GSEA conducted on PCEN defined 
classical and basal-like models identifies EMT as a top pathway enriched in basal-like 
models FDR = 0.000. (f) Pie chart comparison of tumor differentiation status in high 
epithelial content TCGA models (n=76 tumors) comparing co-expression derived 
classifications and Moffitt classifications (left panel). Heat map of C1vC23 anti-correlating 
cluster signature differential, matching Moffitt classification and tumor grade on TCGA 
tumor samples (samples with ≥ 30% epithelial content) (right panel).  
 
5.2.4: Single-cell transcriptomic profiles of tumors define a cell-intrinsic clonal 
signature of PDAC subtypes  
In order to investigate whether the quasi-basal signature identified in bulk tumor 
populations represents a quantifiable cell state or a mean signature derived from 
competing subcellular populations, we conducted single-cell RNAseq (scRNAseq) on the 
PATC69 (quasi-basal), PATC124 (quasi-basal), and PATC53 (basal-like) PDX lines. The 
co-expression network was used to identify cells expressing more than 30% of any 
cluster, and a centroid score for that cluster was calculated using genes with expression 
highly correlated to the cluster enrichment (r > 0.4). By analyzing scRNAseq data in the 
context of the co-expression network, we circumvented the technical issue of signal 
dropout by prioritizing large gene clusters to represent transcriptional diversity rather than 
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single gene expression. Thus, the co-expression network serves as an additional 
resource for disease-specific single cell analysis. This approach successfully confirmed 
the presence of a quasi-basal C1vC23 signature as a quantifiable state in individual cells 
within in each PDX model (Figure 14 A - D), confirming that the bulk readout represented 
an average of the intratumoral spectrum of classical, quasi-basal, and basal-like 



















Figure 14: Intratumoral characterization of anti-correlating CoDEX clusters 
recapitulate a granular and tumor-localized “classical”, “quasi-basal”, and “basal-
like” spectrum. (a - c) UMAP of single-cell sequenced low-passage (a) PATC69 (7857 
cells), (b) PATC124 (9482 cells) and (c) PATC53 (14791 cells) cell lines with an overlay 
of a PCEN-normalized C1v23 signature with respective percentages of cells 
corresponding to each PCEN subtype. Pie chart with distribution of three classifications 
are displayed next to respective UMAPs (percentage). (d) Density histogram of the C1v23 
signature differential distributions of PATC124, PATC53, and PATC69 PDX lines, with 
more positive cluster differential indicating enrichment in Cluster 1 and more negative 







5.2.5: PCEN-informed genetic dependencies functionally validate intratumoral 
classical, quasi-basal, and basal-like molecular signatures 
Integrating CRISPR screen-defined co-dependencies with the co-expression 
network anchors common and unique PDAC dependencies within the larger context of 
PDAC diversity. To determine the functional relevance of this approach, we evaluated the 
effect of perturbing gene targets associated with the basal-like subtype that were 
prioritized through our PCEN analysis in varied tumor contexts (Figure 12B - D, Figure 
15A). Based on our in vitro CRISPR screening results, we selected sgRNA sequences 
targeting SMAD4, ZEB1, and ILK, as well as the non-essential gene, ABCG8, as a 
negative control (Figure 16A). PCEN-informed SMAD4 and ZEB1, both localized within 
the network, were targeted for C1vC23 signature validation. ILK, a CRISPR-defined 
dependency in PATC53 not present in the co-expression network, was also selected to 
determine whether knockout of this potential EMT regulator would also have the capacity 
to influence the C1vC23 signature differential121-123. We then applied a feature barcoding 
strategy whereby a complement sequence was incorporated into the 3’ end of the sgRNA 
sequences, enabling scRNAseq sample multiplexing and quantification of the C1vC23 
signature shift relative to the sgABCG8 negative control distribution (Figure 15B). 
Selected sgRNAs derived from the CRISPR library were transduced into quasi-basal 
PATC69 and basal-like PATC53 cells (Figure 15B). Cells were cultured in vitro and 
collected at the earliest point of essential versus non-essential saturation in the original 
CRISPR screen (Day 20) (Figure 15B, Figure 7C). Sanger sequencing was used to 
analyze the indel frequency of each sgRNA (Figure 15B, Figure 16B - K), and colony 
growth was tracked for each sgRNA to confirm selective growth inhibition in the basal-
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like PATC53 (Figure 15B). Multiplexed scRNAseq was conducted on 10,000 cells total 
(2,500 cells per sgRNA) for each PDX line (Figure 15B). 
PATC53 UMAPs revealed a clear separation between the ABCG8 negative control 
knockout cells and populations with perturbations in combined Cluster 23 (SMAD4 and 
ZEB1) and basal-like (ILK)-associated genes, whereas no separation was observed 
between test genes and the negative control in PATC69 cells (Figure 15C, E). As 
expected, the PATC69 population transduced with negative control sgABCG8 contained 
C1vC23-defined classical and quasi-basal cells, while the basal-like PATC53 population 
contained quasi-basal and basal-like cells (Figure 17C - D). To test the C1vC23 signature 
distribution shift relative to the reference distribution defined by the ABCG8-null negative 
control, C1vC23 density plots were generated for each sgRNA knockout cell line (Figure 
15G - H), and Kolmogorov’s D statistic was used. Deletion of ILK, SMAD4, and ZEB1 
each resulted in a significant C1vC23 shift towards the Cluster 1-enriched classical 
signature in both PATC69 and PATC53 (Figure 15G - H). In parallel with scRNAseq, 
transduced populations were seeded in vitro immediately following selection to compare 
relative growth phenotypes for both PDX lines (Figure 15B). Coinciding with the signature 
shift towards Cluster 1 at the single-cell level, perturbation of each of the three basal-like-
associated genes inhibited bulk population growth in PATC53 relative to sgABCG8-
knockout controls, whereas no growth phenotype was observed in the classical PATC69 






































Figure 15. Functional validation of PCEN-informed intratumoral context 
dependency for C1vC23 associated genetic targets. (a) Force-directed layout of 
prominent anti-correlative cluster centroid trends across the PDAC co-expression 
network highlighting Cluster 1 (Lipid metabolism) vs. Cluster 23 (Cell development) along 
with PATC53 in vivo specific vulnerabilities from our CRISPR screen analysis with size of 
the gene representing the quantile-normalized Bayes factors. (b) Overview of the feature 
barcoding strategy for intratumoral tracking of PCEN signatures following sgRNA 
knockouts. Targeting sgRNAs for ABCG8 (as a negative control), ILK, SMAD4, and ZEB1 
were selected and based on CRIPSR screening results. PATC69 and PATC53 cell 
populations were individually transduced in vitro, selected with Puromycin, and parallel 
assays were also prepared to confirm knockout phenotypes through colony growth, and 
sgRNA cutting through Sanger sequencing. Each knockout cell population was cultured 
in vitro for 22 days (CRISPR screening time-point day 10), and then combined scRNAseq 
library preparation. A total of 10,000 cells per PDX line were sequenced, 2,500 per 
condition. (c) UMAP of the PATC69 PDX line with defined ABCG8, ILK, SMAD4, and 
ZEB1 knockout populations (10113 total cells). (d) Normalized viability of PATC69 cells 
following knockout of ABCG8, SMAD4, ZEB1, ILK, or RPS27A with sgRNA. **p < 0.05. 
(e) UMAP of the PATC53 PDX line with defined ABCG8, ILK, SMAD4, and ZEB1 
knockout populations (11439 total cells). (f) Normalized viability of PATC53 cells following 
knockout of ABCG8, SMAD4, ZEB1, ILK, or RPS27A with sgRNA. *p < 0.05; **p < 0.01. 
(g) Comparative PATC69 density plots of C1vC23 signature following knockout with 
sgILK, sgSMAD4, sgZEB1 and sgABCG8 negative control calculated as the differential 
between the cluster 1 and 23 centroid score, with more positive differential indicating 
cluster 1 enrichment and vice versa. P values and D statistic derived from Kolmogorov 
Smirnov test. (h) Comparative PATC53 density plots of C1vC23 signature in PATC53 































Figure 16: Selection of sgRNAs and validation of site-directed cutting of C1vC23 
associated genetic targets. (a) sgRNAs utilized for CRISPR knockout and feature-
barcode tracking scRNAseq. Guides were selected based on dropout activity in the 
parallel in vitro and in vivo CRISPR screens for PATC69 and PATC53. (b - k) Indel 
frequencies and patterns for selected sgRNAs in both PATC69 and PAYC53. Indel 
frequency was calculated using Sanger sequencing and the Synthego ICE CRISPR 
























Figure 17: Colony formation following sgRNA transduction and intratumoral 
C1vC23 characterization of sequenced PDX populations. (a - b) Crystal violet staining 
of colony growth for PATC69 ([left panel) and PATC53 (right panel). Colonies were 
seeded immediately following puromycin selection (1,500 cells/well), and cultured for a 
minimum 10 doublings to confirm dropout activity relative to the sgABCG8 negative 
control. (c - d) UMAPs detailing the C1vC23 signature in each single-cell RNA sequenced 




            The development, clinical annotation and integration of the PDX-derived PCEN 
with our PDX-focused in vivo functional genomics platform has provided an opportunity 
to anchor identified PDAC dependencies within the larger spectrum of PDAC 
disease diversity. In short, this approach provides a novel way to established context 
for both common and model-specific dependencies based on concordant gene-cluster 
patterns. Upon leveraging a representative PDX cohort to establish the PCEN, we 
identified a prominent anti-correlative cluster signatures contributing to transcriptional 
diversity. Anchoring the CRISPR-defined dependencies of our PDX lines highlighted a 
clear enrichment for PATC53 along the Cluster 1-to-23 anti-correlative axis, with a large 
portion of unique targets anchoring along the Cluster 23 side of the network. Further 
characterization of this differential signature revealed a granular recapitulation of the 
Moffitt signature, and a refined classification of tumors with a near zero cluster differential 
which we termed as “Quasi-basal”. Additionally, GSEA revealed EMT as the most 
enriched signature upon comparison of refined Classical and Basal-like populations. 
Importantly, scRNAseq analysis, utilizing these cluster signatures, confirmed this granular 
signature intratumorally. Implicating that these two Moffitt-based signatures are better 
represented as a spectrum of tumors and not as a binary classification. We leveraged 
PCEN-anchored dependencies to validate this C1vC23 signature, as well the context-
specificity of these targets, using direct capture sgRNA-mediate knockout in combination 




Chapter 6: Discussion 
 
PDAC is a highly lethal malignancy with limited avenues for context-specific 
therapeutic approaches. The importance of establishing therapeutic context for this 
disease is highlighted by the success in Olaparib maintenance therapy in the limited 
cohort of patients with germline mutations in BRCA1 or BRCA29. As mutation-based 
avenues for PDAC patient stratification are limited, current characterization and subtyping 
efforts have focused on transcriptional signatures. Specifically, these transcriptional 
subtyping efforts have predominantly been focused around the categorical Moffitt 
classical and basal-like subtypes, which have the capacity to stratify patients based on 
clinical outcome10,11. While these Moffitt subtypes serve to aid in informing on patient 
prognosis, the refined gene signature utilized in the consensus clustering of PDAC tumors 
does aid in informing on potential vulnerabilities.  
To address this, we developed an integrated platform to anchor CRISPR-defined 
dependencies, identified through disease-prioritized functional genomics platform, within 
clinically-annotated molecular signatures contributing to PDAC disease diversity. 
Specifically, we leveraged a PDX cohort as the foundation for a tumor-intrinsic PDAC co-
expression network (PCEN) in order to refine and annotate gene-clusters contributing to 
transcriptional diversity. In parallel, custom PDAC-prioritized RNAi and CRISPR libraries 
were utilized expand on and annotate oncogenic signaling diversity in a subset of this 
PDX cohort.  
First, within the PCEN, we identified a prominent differential signature derived from 
anti-correlating Clusters 1 and 23 (C1vC23), which served to granularly recapitulate a 
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Moffitt classical to basal-like continuum. In addition, differential signaling between 
C1vC23-refined classical and basal-like tumors identified an EMT signature as a potential 
driver. Refined basal-like tumors, enriched by Cluster 23, were GO annotated by gene 
signatures corresponding to cell projection, motility and developmental pathways, 
supporting the idea of a mesenchymal phenotype119. Interestingly, Cluster 1 refined 
classical tumors exhibited GO signatures associated to lipid metabolism and hormone 
regulation. Lipid droplets and lipid metabolism have been previously characterized as 
playing important roles in pancreatic cancer124. Interestingly, classical tumor signatures 
have not yet been associated towards the need for lipid metabolism or fatty acids for 
tumor proliferation, highlighting the advantage of leveraging a more comprehensive 
approach for defining disease diversity in pancreatic cancer. Another, notable attribute of 
the C1vC23 signature is the refinement of clinical features in the C23-enriched basal-like 
cohort in both PDX and TCGA datasets. This refinement of clinical features was due to 
the ability of the C1vC23 signature to separately distinguish a group of tumors with a near-
zero differential signature, which we termed quasi-basal, and remove these partially 
expressing C23 tumors from the basal-like cohort. Specifically, these tumors exhibit no 
enrichment in Cluster 1 or Cluster 23, and instead express both gene signatures at low 
level. Furthermore, we performed scRNAseq on all three of the PDX lines utilized for 
CRISPR screening, and showed that this quasi-basal signature is not simply a result of 
two competing subclones. This finding expands on the work derived from the recently 
published Toronto classification approach, which highlighted co-occurrence of classical 
and basal-like clones in PDAC tumors10,13.  
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Along with comprehensively quantifying transcriptional signatures contributing to 
disease diversity, the other arm of our unbiased platform sought to quantify oncogenic 
signaling diversity in PDAC, starting from the surfaceome. We started with a PRAC-
prioritized shRNA library targeting proteins localized to the cell surface in an effort to 
identify a more comprehensive list of oncogenic drivers in our PDX lines, understand how 
concordant these targets are across models, and finally compare in vivo vs. in vitro growth 
conditions during genetic screening. Along with identifying a clear distinction between in 
vivo vs. in vitro dependencies following RSA analysis, we identified several novel surface-
protein targets that have never been previously annotated in PDAC. Furthermore, we 
performed the necessary rescue assays needed to confirm CD109 as a novel RNAi-
derived hit and potential oncogene in PDAC. However, along with developing projects 
with a single-gene focus, we also sought to develop an in vivo CRISPR functional 
genomics platform in order to provide a more precise, sensitive and comprehensive view 
of these RNAi-defined surface protein dependencies. In order to address potential 
signaling redundancy from cell surface oncogenes, we utilized a refined STRING ppi 
network to expand on these original RNAi-defined dependencies. This ppi network, along 
with providing a foundation for sgRNA library development, subsequently served as a 
foundation for the comparison of Bayes factor refined dependency networks. Merging 
these dependency networks based on common nodes highlighted the distinct and unique 
dependencies in PATC53, a C1vC23 enriched basal-like model, compared the 
interconnected dependencies of quasi-basal PATC124 and PATC69.  
Upon anchoring these CRISPR-defined hits within the PCEN, we identified a clear 
enrichment of unique PATC53 dependencies along the Cluster 23 axis of the network. In 
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order to validate the context-specificity of these Cluster 23 associated targets, as well as 
validate the C1vC23 signature itself, we applied a feature-barcoded scRNAseq to inform 
on intratumoral C1vC23 distributions following CRISPR knockout of select targets. 
Specifically, we performed multiplexed CRISPR deletion of several targets associated to 
the Cluster 23 basal-like enrichment, including ILK, SMAD4, and ZEB1. As an internal 
control, we also included an sgRNA for knockout of non-essential ABCG8. Knockout of 
these Cluster 23 associated targets, showed a substantial “subclonal shift” toward the 
classical signature for both quasi-basal PATC69 and basal-like PATC53, when compared 
to the ABCG8 C1vC23 distribution. Thus, implicating that CRISPR-defined gene target 
essentiality identified in pooled screens is dependent on the clonal representation within 
the tumor. Furthermore, Cluster 23 depletion, following knockout of known mesenchymal 
drivers SMAD4 and ZEB1, served to genetically validate this network-derived signature. 
Our findings are also consistent with the previously characterized dual PDAC tumor 
suppressor and oncogenic roles of SMAD4, based on the molecular context characterized 
by C1vC23120.  
Our functionally-anchored PCEN platform also provides unique avenues for 
hypothesis generation within the context of gene-cluster signatures. We identified several 
novel and largely unstudied targets (NKAIN4 and FAM171A2) associated to Cluster 23 
enrichment. In addition, depletion in FAM171A2 was also identified to be most significant 
basal-like PATC53 and PATC153 in the original RNAi screens, as compared to quasi-
basal PATC69 and PATC124. Although we focused on basal-like vulnerabilities for 
intratumoral validation, we also identified Cluster 1 enriched dependencies in PATC69 
(DNM2) that might serve to selectively deplete these more classical populations. 
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Importantly, these findings highlight the need to move beyond tumor shrinkage 
when studying the effects of gene perturbation in cancer. In order to address tumor 
reoccurrence, the effect of signaling perturbation on intratumoral heterogeneity is likely 
more important than how essential a gene target initial is. One novel potential strategy for 
PDAC treatment could be to apply selective genetic or signaling perturbation in order to 
first bottleneck tumor heterogeneity, and then follow-up with treatment based on the 
excepted clonal composition of the tumor. With the advent of direct-capture Perturb-seq, 
it is now possible to introduce and capture multiple sgRNAs per cell for scRNAseq 
analysis125. Leveraging the PCEN, cluster-level node centrality could potentially be 
leveraged as a metric to build custom prioritized libraries in order to identify gene targets 
that most influence the C1vC23 signature in intratumoral populations. Furthermore, we 
could also test whether dual knockout of Cluster 1 and Cluster 23 gene targets results in 
a tumor completely composed of quasi-basal cells. In addition, if this experiment was 
performed on barcoded populations by utilizing a lentiviral vector that expresses barcodes 
in the UTR of mRNA transcripts, we would be able to track the effect of combinatorial 
perturbation at a clonal level, rather than only tracking population dynamics. This 
approach could also be paired with whole genome CRISPR screening data in order to 
quantitatively define targets that force C1vC23 signature shift through transcriptomic 
alteration vs. selective clonal ablation.  
Multiple additional layers of information could also serve to expand the network 
beyond transcriptional signatures. Along with integrating the PCEN with whole genome 
CRISPR data for each PDX line, integrating patterns at the protein level, for example “co-
phosphorylation”, along with epigenetic and copy-number information, could aid in 
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providing more context to these gene-cluster patterns, and identify potential druggable 
targets that might be associated to a cluster signature but not a part of the cluster. Finally, 
applying co-expression networks to define signaling variance derived from the tumor 
microenvironment, could also serve to provide an additional layer to understanding 
external forces driving tumor diversity. For example, tumor response to chemotherapy or 
immunotherapy. Only through careful tumor modeling and by continuing to 
integrate a multi-faceted approach towards tumor characterization (genomic, 
transcriptomic, proteomic, functional, etc.) can we begin to more comprehensively 
understand the intrinsic and external factors contributing towards disease 
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